The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
### Title and Subtitle
Genetic and Physiological Studies of Bacillus Anthracis Related to Development of an Improved Vaccine

### Authors
Curtis B. Thorne

### Performing Organization
University of Massachusetts
203 Morrill Science Center, Box 35720
Amherst, Massachusetts 01003-0081

### Abstract
Most of our effort was spent on studies concerning the biology of the two B. anthracis plasmids, pXO1 which encodes toxin synthesis and pXO2 which encodes capsule synthesis. Analysis of Tn917 insertion mutants of pXO1 revealed several mutants that were altered in toxin production. In some instances, the altered phenotypes were the result of insertions within or deletions of one or more of the toxin structural genes. Analysis of another mutant, deficient in production of all three toxin components, led to the discovery and cloning of a gene, abx4, involved in trans-activation of toxin synthesis. Overproduction of toxin by another mutant suggested that Tn917 had inserted in a negative regulatory gene. Restriction analysis and physical mapping of pXO1 from several B. anthracis strains revealed an inversion of the toxin-encoding region of pXO1 from the Sterne strain. The inverted segment was found to be flanked by imperfect 1336-bp inverted repeats, each containing a sequence resembling a full or truncated IS150-like transposase gene. Comparison of Sterne and Weybridge B. anthracis strains revealed no differences in phenotypes that could be associated with the inversion. Studies of insertion mutants of pXO2 suggested that some of the mutations are located in genes regulating synthesis of capsules. Among such mutants are those that overproduce capsular material, some that no longer require bicarbonate and CO₂ for capsule synthesis, and some that have lost the ability to synthesize capsules.

### Subject Terms
- Capsule
- Protective antigen
- B. anthracis
- Plasmid pXO1
- Transposon mutagenesis
- Anthrax toxin
- Plasmid pXO2
- Regulatory genes

### Security Classification
Unclassified

### Distribution Statement
Approved for public release; distribution unlimited

### Number of Pages
77
Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.
TABLE OF CONTENTS

FINAL REPORT ............................................................... 4

MATERIALS AND METHODS .................................................. 4

RESULTS AND DISCUSSION ................................................ 11

I. Physical and genetic analysis of B. anthracis toxin plasmid pXO1 ........................................ 11
   Quantitative analysis of toxin production by several insertions mutants ............................. 12
   Analysis of altered BamHI-SalI fragments of pXO1.1::Tn917 deletion derivatives
      from UM23 tp21 and tp39 ................................................................ 12
   Attempts to Purify UM23 tp49 and tp71 ........................................................................ 13
   Genetic analysis of atxA gene ......................................................................................... 13

II. Analysis of an Inversion Encompassing the Toxin-Encoding Region of
    pXO1.1 (Weybridge A) and pXO1 (Sterne) ................................................................. 15
    Restriction analyses of pXO1 from several B. anthracis strains ...................................... 16
    Analysis of the PstI restriction map of the 34.8-kb BamHI fragment of
      pXO1.1 (Weybridge A UM23) ..................................................................................... 17
    EcoRI restriction mapping of pXO1.1 (Weybridge A) .................................................... 19
    Cloning of the EcoRI fragments of pXO1.1 (Weybridge A) and pXO1 (Sterne)
      encompassing the junctions of the inverted segment .................................................. 21
    Subcloning of the cloned EcoRI fragments of pXO1.1 (Weybridge A) and
      pXO1 (Sterne) containing the junctions of the inverted segment ................................ 22
    DNA-DNA hybridization analysis of pXO1.1 (Weybridge A) and pXO1 (Sterne) with the
      cloned junction fragments of the inverted toxin-encoding region ................................ 23
    Determination and analysis of the sequences of the cloned junctions fragments of the
      inverted segments of pXO1.1 (Weybridge A) and pXO1 (Sterne) ................................ 23
    Distribution of inverted repeats ....................................................................................... 25
    Lack of correlation of observed phenotypes with orientation of the inverted segment ...... 25

III. Physical and genetic analysis of the B. anthracis capsule plasmid pXO2 ............................. 26
    Restriction analyses of the Tn917-tagged pXO2 derivatives from
      B. anthracis 4229 UM12 ......................................................................................... 26
    Analysis of insertion mutants that appear to be polypeptide overproducers .................... 27
Quantitative determination of glutamyl polypeptide produced by overproducing mutants .............................................. 28
Determination of the configuration of glutamic acid in glutamyl polypeptide produced by *B. anthracis* 4229 UM12 and insertion mutants tp49, tp50, and tp60 .................. 28
Transduction of the chromosomal insertion mutation from *B. anthracis* 4229 UM12 tp50 to wild-type strains ........................................ 29
Analysis of pXO2::Tn917 from mutant tp24-17, a deletion derivative .................. 30
Transduction of pUBCAP1 from *B. anthracis* Davis TE704 to *B. anthracis* 4229 UM12C1 and insertion mutants 4229 UM12 tp6 and tp38 .................. 31
Attempts to clone the 2.8-kb HindIII and the 10.5-kb Clal fragments into an *E. coli* host ........................................ 31

IV. Investigation of phage TP-21 whose prophage is a plasmid ........................................ 32

CONCLUSIONS ........................................................................ 33

Table 1. Bacterial strains and plasmids used in this report ........................................ 34
Table 2. Yields of toxin components produced by *B. anthracis* Weybridge A UM23 and UM23 insertion mutants grown in the absence of added bicarbonate and horse serum .... 40
Table 3. Origins of the altered BamHI-SalI fragments of pXO1.1::Tn917 deletion derivatives from UM23 tp21 and tp39 ........................................ 41
Table 4. Production of anthrax toxin components by *B. anthracis* strains complemented with the cloned atxA gene ........................................ 42
Table 5. Yields of toxin components produced by *B. anthracis* Weybridge A UM23 tp39 and tp39 electrotransformants ........................................ 43
Table 6. Restriction analysis of the 14-kb BamHI fragment of pXO1.1 (Weybridge A UM23) .... 44
Table 7. EcoRI digestion of BamHI-SalI fragments of pXO1.1::Tn917 derivatives from *B. anthracis* Weybridge A UM23 tp2A, tp36, and tp62 ........................................ 45
Table 8. DNA-DNA hybridization analysis of pXO1.1 (Weybridge A UM23) and pXO1 (Sterne) with the subcloned fragments of each plasmid containing the junctions of the inverted segment ........................................ 46
Table 9. Yields of toxin components produced by *B. anthracis* Sterne and Weybridge derivatives 47
Table 10. Configuration of glutamic acid in glutamyl polypeptide from *B. anthracis* 4229 UM12 and insertion mutants tp49, tp50 and tp60 ........................................ 48

Figure 1. BamHI, PstI, and EcoRI restriction maps of the toxin-encoding region of pXO1.1 (Weybridge A UM23) ........................................ 49
Figure 2. Construction of EcoRI and Clal restriction maps of the 14.6-kb BamHI fragment of pXO1.1 (Weybridge A UM23) ................................. 44

Figure 3. Cloning of the 2.4- and 5.4-kb EcoRI fragments of pXO1.1 (Weybridge A UM23) and the 3.1- and 4.8-kb EcoRI fragments of pXO1 (Steme) .......................... 50

Figure 4. Subcloned inserts originating from the 2.4-kb and 5.4-kb EcoRI fragments from pXO1.1 (Weybridge A UM23) and the 3.1-kb and 4.8-kb EcoRI fragments from pXO1 (Steme) . 51

Figure 5. Comparison of restriction maps of the toxin-encoding regions of pXO1.1 (Weybridge A UM23) and pXO1 (Steme) ............................. 52

Figure 6. Sequencing strategies for the cloned junction fragments of the inverted segments of pXO1.1 (Weybridge A UM23) and pXO1 (Steme) ..................................... 53

Figure 7. Nucleotide sequence of the cloned insert (WeyAL) from pJMH12 (2.7-kb KpnI fragment of the 5.4-kb EcoRI fragment of pXO1.1 from Weybridge A UM23) .......... 55

Figure 8. Nucleotide sequence of the cloned inserts (WeyAR) from pJMH24 (1.0-HindIII fragment of the 2.4-kb EcoRI fragment of pXO1.1 from Weybridge A UM23), pJMH4 (2.4-kb EcoRI fragment), and pJMH28 (9.3-kb PsiI fragment of pXO1.1 from Weybridge A UM23) ............................................. 57

Figure 9. Nucleotide sequence of the cloned insert (StemeL) from pJMH16 (1.9-kb KpnI fragment of the 4.8-kb EcoRI fragment of pXO1 from Steme) ........................................ 59

Figure 10. Nucleotide sequence of the cloned inserts (StemeR) from pJMH20 (1.7-kb HindIII fragment of the 3.1-kb EcoRI fragment of pXO1 from Steme) and pJMH5 (3.1-kb EcoRI fragment) ........................................ 61

Figure 11. Bestfit of sequences of WeyAR and WeyAL ................................ 63

Figure 12. Bestfit of sequences of StemeL and StemeR ............................. 65

Figure 13. Partial restriction maps of the junction fragments of the toxin-encoding regions of pXO1.1 (Weybridge A UM23) and pXO1 (Steme) ............................. 67

Figure 14. Locations of major ORFs in the cloned junction fragments of the inverted segments of pXO1.1 (Weybridge A UM23) and pXO1 (Steme) .......................... 68

Figure 15. Restriction map of pXO2 ................................................ 69

REFERENCES ......................................................................... 70

APPENDIX ........................................................................ 73
FINAL REPORT

This is the final report submitted under contract DAMD17-91-C-1100. Research on the contract which began June 30, 1991 is a continuation of research previously carried out under contract DAMD17-85-C-5212.

During the three years represented by this report our research concentrated largely on (i) physical and genetic analysis of the \textit{B. anthracis} toxin plasmid pXO1; and (ii) physical and genetic analysis of the \textit{B. anthracis} capsule plasmid pXO2. A very small proportion of our effort was also directed toward development of the bacteriophage TP-21 as a vector for transposon mutagenesis.

In this report our main efforts are described and discussed following a general description of materials and methods. Specific procedures which themselves are results of the research are described as appropriate under individual sections.

MATERIALS AND METHODS

**Organisms.** Table 1 lists the bacterial strains and plasmids referred to in this report.

**Media.** For convenience to the reader, compositions of the various culture media referred to in this report are given below. All amounts are for one liter final volume. For preparation of solid medium, 15 grams of agar (Difco) were added per liter of the corresponding broth.

- **NBY broth:** Nutrient broth (Difco), 8 g; Yeast extract (Difco), 3 g.
- **Phage assay (PA) broth:** Nutrient broth (Difco), 8 g; NaCl, 5 g; MgSO\textsubscript{4} \cdot 7H\textsubscript{2}O, 0.2 g; MnSO\textsubscript{4} \cdot H\textsubscript{2}O, 0.05 g; CaCl\textsubscript{2} \cdot 2H\textsubscript{2}O, 0.15 g. The pH was adjusted to 6.0 with HCl.
- **Phage assay agar:** For bottom agar, 15 g of agar were added per liter of phage assay broth. For soft agar, 0.6 g of agar were added per liter.
- **L broth:** Tryptone (Difco), 10 g; Yeast extract (Difco), 5 g; NaCl, 10 g. The pH was adjusted to 7.0 with NaOH.
- **LPA agar:** L agar containing the salts of PA broth.
- **LPACO\textsubscript{3} agar:** LPA agar with 5 g of NaHCO\textsubscript{3}.
- **LG broth:** L broth with 1 g of glucose.
- **BHI broth:** Brain heart infusion broth (Difco), 37 g.

**Peptone diluent:** Peptone (Difco), 10 g. Used for diluting phage and bacterial cells.

**Minimal I:** (NH\textsubscript{4})\textsubscript{2}SO\textsubscript{4}, 2 g; KH\textsubscript{2}PO\textsubscript{4}, 6 g; K\textsubscript{2}HPO\textsubscript{4}, 14 g; trisodium citrate, 1 g; glucose, 5 g; L-glutamic acid, 2 g; MgSO\textsubscript{4} \cdot 7H\textsubscript{2}O, 200 mg; FeCl\textsubscript{3} 6H\textsubscript{2}O, 40 mg; MnSO\textsubscript{4} \cdot H\textsubscript{2}O, 0.25 mg. The pH was adjusted to 7.0 with NaOH. The glucose and FeCl\textsubscript{3} were sterilized separately.
Minimal IB: The basal medium is the same as Minimal I except that FeSO$_4$ (14 mg) is substituted for FeCl$_3$ and MnSO$_4$$	extcdot$H$_2$O is increased to 12.5 mg. The following are added: thiamine hydrochloride, 10 μg; and 160 μg each of L-methionine, L-leucine, L-valine, L-alanine, L-serine, L-threonine, L-proline, and L-phenylalanine.

Minimal IC: Minimal I with 5 g of Vitamin-Free Casamino Acids (Difco) and 10 mg of thiamine hydrochloride.

Minimal IIIB: (NH$_4$)$_2$SO$_4$, 2.0; KH$_2$PO$_4$, 6.0; KH$_2$PO$_4$, 14.0; trisodium citrate, 1.0; MgSO$_4$·7H$_2$O, 0.4; MnSO$_4$·H$_2$O, 0.05; CaCl$_2$·2H$_2$O, 0.15; FeSO$_4$, 0.02; glucose, 5.0; thiamine-HCl, 0.01; nicotinamide, 0.01; glycine, 0.40; L-glutamic acid, 0.40; and 0.32 g each of L-leucine, L-valine, L-alanine, L-serine, L-threonine, L-proline, L-phenylalanine, L-glutamine, L-histidine, L-arginine, L-isoleucine, L-asparagine, and L-methionine.

Minimal XO: To Minimal I are added 10 mg of thiamine hydrochloride, 200 mg of glycine, and 40 mg of L-methionine, L-serine, L-threonine, and L-proline.

CA broth is the Casamino Acids medium as described by Thome and Belton (24).

CA-agarose medium: CA-agarose medium for the detection of colonies producing protective antigen was prepared as follows: 0.75 g of agarose was added to 100 ml of CA broth, prepared as described by Thome and Belton (24), and the mixture was steamed until the agarose was dissolved. When the medium cooled to about 50°C, 1 ml of 20% glucose, 8 ml of 9% NaHCO$_3$, 6 ml of goat antiserum to B. anthracis and 10 ml of horse serum were added. The medium was dispensed in petri plates (13 ml per plate) and the plates were left with their lids ajar while the agarose solidified. The plates were usable after 1 h.

Quantitative determination of PA, LF, and EF. In some instances, the culture filtrates were concentrated 2- to 40-fold by ultrafiltration in Centricon 30 microconcentrator units (Amicon, Beverly, MA). The amount of PA and LF in the sample filtrates were determined by a radial immunodiffusion assay. The radial immunodiffusion agarose medium consisted of 1% Seakem GTG agarose (FMC BioProducts, Rockland, ME), 2% polyethylene glycol 8000, 3% fetal bovine serum, 20 mM HEPES (pH 7.5), 0.15 M NaCl, 2 mM EDTA, 0.025% sodium azide, and either 0.5% goat antiserum to PA or 0.7% rabbit antiserum to LF. A well approx. 2.5 mm in diameter was cut into the agarose medium and 8 μl of the filtrate was added to each well. Each plate included a set of standards containing 5 to 50 μg of purified PA or LF per ml. The diameter of the precipitin ring was measured and the data were compared to a standard curve.

EF in the culture filtrates was determined by an adenylate cyclase assay according to a method described by Leppla (11). A set of standards containing 0.05 to 1 μg of purified EF per ml was included in each assay. Briefly, approx. 10 μl of sample filtrate or purified EF standard were mixed with 40 μl of a reaction mixture containing 50 mM HEPES (pH 7.5), 12.5 mM MgCl$_2$, 2.5 mM dithiothreitol, 1.25 mM CaCl$_2$, 1.25 mM EDTA, 1.25 mM ATP, 0.25 mM cyclic AMP, 2.5 mg of bovine serum albumin, fraction V per ml, 25
µg of calmodulin (Sigma Chemical Co., St. Louis, MO) per ml, and 1.25 µCi of α-32P-ATP per ml. The reactions were incubated for 10 min at room temperature. The reactions were stopped by adding 100 µl of a stopping solution containing 1% SDS, 50 mM ATP, and 1.25 mM cyclic AMP. Approx. 1 ml of distilled water was added to each tube.

The radiolabelled cyclic AMP product was separated from the nonreacted radiolabelled ATP reactant by sequential chromatography on cation exchange and aluminum oxide (Alumina) columns. The reaction mixtures were poured over Dowex AG 50W-X4 (200-400 mesh) columns that had been washed previously with 2 X 8 ml of distilled water. When the mixtures had drained into the columns, the columns were washed twice with 1.5 ml of distilled water to elute the nonreacted radiolabelled ATP. Any radiolabelled material left on the column was eluted with 5 ml of distilled water directly onto neutral Alumina WN-3 columns which had been washed previously with 8 ml of 0.1 M Imidazole (pH 7.3). Once the effluent from the Dowex 50 columns had drained into the Alumina columns, the radiolabelled cyclic AMP was eluted with 6 ml of 0.1 M Imidazole (pH 7.3) directly into 7-ml scintillation vials. The sample effluents were then counted in a Beckman LS5000 TD scintillation counter. The Dowex 50 columns were recycled by washing them twice with 2 ml of 1 M HCl and the Alumina columns were recycled by washing them with 3 ml of 0.1 M Imidazole (pH 7.3). The data obtained for the culture filtrates was compared to a standard curve prepared for purified EF.

Transfer of DNA to nylon membranes. DNA electrophoresed on an agarose gel was transferred to a Magnagraph nylon membrane (Micron Separations Inc., Westboro, MA) using a modified method of that described by Boehringer Mannheim Corp. (Technical Update [Nov. 1990], Indianapolis, IN). The DNA in the gel was acid nicked by incubation in 0.25 N HCl for 10 to 15 min. The gel was rinsed in distilled water and placed in 0.5 N NaOH-1.5 M NaCl for 30 min with gentle agitation to denature the DNA. The gel was then neutralized in 1.5 M NaCl-1.0 M Tris-HCl (pH 8.0) for 1 h with gentle agitation. The DNA was blotted from the neutralized gel onto a Magnagraph nylon membrane by capillary transfer using 10X SSC for 12 to 16 h. After the transfer, the membrane was gently washed in 6X SSC for 5 min, air dried for 1 h, and then baked at 80°C in a vacuum oven for 1 to 2 h. The membrane was either used immediately for hybridization or stored in a dry place for use later.

Labelling probe DNA with digoxigenin-11-dUTP. Digoxigenin-11-dUTP was incorporated into the probe DNA by random primer labelling according to a method described for nonradioactive labelling of DNA by Boehringer Mannheim Corp. (Indianapolis, IN). The hexanucleotide mixture, digoxigenin DNA labelling mixture, and the Klenow fragment were purchased from Boehringer Mannheim Corp. The reaction was carried out in a final volume of 50 µl in a 1.5-ml microcentrifuge tube. The probe DNA was denatured by placing the DNA solution in a boiling water bath for 10 min and then quickly chilling the solution for 3 min in an ice/ethanol bath. Each reaction mixture contained approx. 1 to 3 µg of denatured DNA, 5 µl of hexanucleotide mixture, 5 µl of digoxigenin DNA labelling mixture, and enough sterile distilled
water to bring the volume to 47.5 μl. DNA synthesis was started by adding 2.5 μl of Klenow fragment. The reactants were gently mixed and placed in a 37°C water bath for 16 to 20 h.

To terminate the reaction, 5 μl of 0.2 M disodium EDTA (pH 8.0) was added to the reaction mixture. The labeled DNA was precipitated with 1 μl of a glycogen solution (20 mg/ml), one-tenth volume of 4 M LiCl, and 3 volumes of 100% ethanol. The precipitation was carried out for 4 to 6 h at -20°C. The labeled DNA was collected by centrifugation and the DNA pellet was washed once with 70% ethanol. A dry DNA pellet was then resuspended in 50 μl of TE (10 mM Tris-HCl, 1 mM disodium EDTA, pH 7 to 8) containing 0.1% SDS for 10 min at 37°C. Prior to hybridization, the digoxigenin-labelled DNA probe was denatured in prehybridization solution by heating in a boiling water bath for 10 min and chilling the mixture quickly in an ice/ethanol bath for 3 min.

**DNA-DNA hybridization.** DNA-DNA hybridizations were done according to a method described by Boehringer Mannheim Corp. for nonradioactive DNA labelling and detection. The Magnagraph nylon membrane containing the immobilized DNA was prehybridized in a sealed plastic bag at 68°C for 1 to 3 h in 20 ml of freshly prepared 5X SSC solution containing 0.1% (w/v) sodium N-lauroylsarcosine, 0.02% (w/v) SDS, and 1% (w/v) Genius blocking reagent (Boehringer Mannheim) per 100 cm² of membrane. After prehybridization, the solution covering the membrane was replaced with 2.5 ml of prehybridization solution containing 250 ng to 1 μg of denatured digoxigenin-labelled DNA probe per 100 cm² of membrane. The bag was sealed and the hybridization was continued at 68°C for 16 to 24 h.

The membrane was removed from the hybridization solution, washed twice in 2X SSC containing 0.1% SDS for 5 min at room temperature, and washed twice in 0.1X SSC containing 0.1% SDS for 15 min at 68°C with gentle shaking. The hybridized DNA probe was detected on the membrane by chemiluminescence.

**Chemiluminescent detection of hybridized DNA.** The method for detecting the hybridized DNA probe with Lumi-Phos 530 solution was described by Boehringer Mannheim Corp. After post-hybridization washes, the membrane was equilibrated for 1 min in Buffer A (100 mM Tris-HCl, 150 mM NaCl, pH 7.5). The membrane was transferred to Buffer B (Buffer A containing 2% (w/v) Genius blocking reagent) for 3 h with gentle shaking. The membrane was then transferred to 30 ml of a 1 to 5000 dilution of an anti-digoxigenin alkaline phosphatase antibody conjugate (diluted in Buffer B) per 100 cm² of membrane. The membrane was incubated in this solution for 30 min with gentle shaking. After the 30-min incubation, the membrane was washed two times for 15 min in Buffer A and then equilibrated for 2 min in Buffer C (100 mM Tris-HCl, 100 mM NaCl, 50 mM MgCl₂, pH 9.5). Finally, the membrane was placed on a clean sheet of acetate film with DNA side up and 2 to 3 ml of Lumi-Phos 530 (Boehringer Mannheim Corp.) was placed directly onto the membrane. A second sheet of acetate film was placed on top of the filter to spread the solution evenly over the membrane. The reaction was allowed to proceed for 15 to 30 min before the membrane (placed in a sealed bag) was exposed to X-ray film (Kodak XAR film). The membrane was
exposed to the X-ray film for 1 to 30 min and the X-ray film was developed according the instructions provided by the manufacturer.

**Isolation of pBluescriptIKS⁺.** The pBluescriptIKS⁺ was isolated from *E. coli* DH₅⁺(pBluescriptIKS⁺) by a modification of a boiling lysis method (14). Twelve ml of an overnight culture of *E. coli* DH₅⁺(pBluescriptIKS⁺) grown in L broth containing 100 μg of ampicillin per ml was centrifuged at 10,000 rpm for 10 min. The pellet was resuspended in 0.7 ml of 8% sucrose/5% triton X-100/50 mM EDTA/50 mM Tris-HCl (pH 8) and the suspension was transferred to a 1.5-ml microcentrifuge tube. Fifty μl of a freshly prepared 10 mg/ml solution of lysozyme in 0.25 M Tris-HCl (pH 8) was added to the cell suspension and the mixture was placed in a boiling water bath for 1 min. The lysed mixture was centrifuged for 15 min at room temperature and the cell debris was removed with a sterile toothpick. Ten μl of a RNAse solution (10 mg/ml) was added to the supernatant and placed at 37°C for 15 min. An equal volume of a 1:1 mixture of phenol-chloroform was added to the tube and gently mixed. The mixture was centrifuged to separate the phases. The aqueous layer was transferred to a fresh tube and the phenol-chloroform extraction was repeated until no white interface was detected (usually 4 to 7 extractions). The final extraction was with an equal volume of 24:1 chloroform-isooamyl alcohol mixture.

The DNA was precipitated with 0.15 volume of 7.5 M ammonium acetate and an equal volume of cold isopropanol. The DNA was allowed to precipitate at -20°C for 20 min. The precipitated DNA was then recovered by centrifugation in a refrigerated microcentrifuge at 13,000 rpm for 30 min. The pellet was washed with 1 ml of cold 70% ethanol. The DNA was then allowed to air dry for 1 h and resuspended in 100 μl of TE (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).

**Preparation of vector for ligation.** Approximately 20 μg of plasmid DNA was digested to completion with an excess amount of restriction endonuclease. The DNA was precipitated overnight at -20°C with one-tenth volume of 3 M sodium acetate (pH 5.2) and 2 volumes of 95% ethanol. The DNA was collected by centrifugation in a refrigerated microcentrifuge at 13,000 rpm for 30 min and washed with 1 ml of cold 70% ethanol. The pellet was allowed to air dry and then resuspended in 50 μl of TE (pH 8). Twenty μl was frozen at -20°C for use as a control in the ligation reactions.

The remaining DNA was treated with calf-intestine alkaline phosphatase (Promega Corp., Madison, WI) according to manufacturer's instructions. Briefly, the volume of the DNA suspension was brought to 40 μl with TE (pH 8). Five μl of a 10X reaction buffer containing 0.5 M Tris-HCl, pH 9, 10 mM MgCl₂, 1 mM ZnCl₂, and 10 mM spermidine and 2 μl of calf-intestine alkaline phosphatase (CIAP) were added to the DNA suspension. The mixture was placed at 37°C for 30 min. Another 2 μl of CIAP was added to the mixture and again placed at 37°C for 30 min. The reaction was stopped by the addition of 300 μl of solution containing 10 mM Tris-HCl, pH 7.5; 1 mM EDTA, pH 7.5; 200 mM NaCl; and 0.5% SDS. The mixture was placed at 60°C for 15 min. The DNA was then extracted with phenol-chloroform and the aqueous phase was precipitated with 0.5 volume of 7.5 M ammonium acetate and 2 volumes of 95%
ethanol. The precipitated DNA was collected by centrifugation, allowed to air dry, and finally resuspended in a total volume of 50 μl TE (pH 8).

**Elution of DNA restriction fragments.** Two methods were employed for isolating restriction fragments from agarose gels. In the first method elution of fragments was carried out using an Elutrap electroseparation chamber according to the manufacturer's instructions (Schleicher and Schuell, Inc., Keene, NH). The elution was run at 200 V for 2 to 3 h and the DNA was collected in 400 to 500 μl of 1X Tris-borate buffer. The DNA was then precipitated with one-tenth volume of 3 M sodium acetate (pH 5.2) and 2 volumes of 100% ethanol. The DNA was collected by centrifugation in a microcentrifuge at 4°C for 30 min. The DNA pellet was dried for 30 min at room temperature and resuspended in 50 μl of TE.

In the second method DNA fragments were transferred from agarose gels by electrophoresis onto DE-81 paper (Whatman, Inc., Clifton, NJ) and eluted from the paper according to a modification (A. Simon, personal communication) of a protocol described by Sambrook et al. (18) and Ausubel et al. (1). The agarose gels containing 0.5 μg of ethidium bromide per ml were prepared and run in 0.5X TBE. Following electrophoresis each restriction fragment to be eluted was cut from the gel under long wave UV light. A piece of DE-81 paper cut to the size of a gel slice and soaked in 0.5X TBE was placed on one side of each slice. Each slice was then placed in a slot of appropriate size in a second agarose gel which was free of DNA. The fragments were electrophoresed onto the paper for 15 to 20 min at 50 V.

The paper was then placed in the bottom of a 0.6-ml microcentrifuge tube containing a hole made with a 25 gauge needle. The 0.6-ml tube was placed into a 1.5-ml microcentrifuge tube and the paper was washed two times with 75 μl of a low salt wash buffer (10 mM Tris-HCl, pH 7.5; 1 mM EDTA, pH 7.5; and 0.1 M LiCl). The samples were centrifuged for 5 s at room temperature. The 0.6-ml tube containing the paper was placed inside a new 1.5-ml microcentrifuge tube. The DNA fragments were eluted from the paper by adding 75 μl of a high salt buffer (20% ethanol; 1 M LiCl; 10 mM Tris-HCl, pH 7.5; and 1 mM EDTA, pH 7.5) to the 0.6-ml tube and incubating the tubes at 65°C for 10 min. The elution mixture was collected in the 1.5-ml tube by centrifugation for 5 s at room temperature. The paper was washed with 75 μl of the high salt wash buffer and the wash was collected in the same 1.5-ml tube by centrifugation for 5 s at room temperature. The DNA fragments were precipitated by adding 300 μl of cold 100% ethanol to the 150-μl elution mixture and placing the mixture at -20°C for 20 min. The precipitated DNA was collected by centrifugation for 5 min at room temperature. The DNA pellet was washed twice with 0.5 ml of cold 70% ethanol and dried either at room temperature for 1 h or in a SpeedVac for 5 min. The pellet was resuspended in 5 μl of sterile distilled water by placing the tube at 65°C for 2 min and at 4°C overnight.

**Ligation reactions.** Ligation reactions were carried out according to methods described by Sambrook et al. (18). Vector and insert DNA were mixed at a molar ratio of 1:3 in a total volume of 10 to 20 μl. Control ligations included digested vector alone to determine whether the ligation was successful and ClAP-treated digested vector alone to determine if the ClAP treatment had reduced vector religations. The concentration of DNA used in the control ligation was the same as that used for the vector in the
vector/insert ligation mixture. The mixtures were heated at 65°C for 5 min and chilled on ice for 5 min to melt any reannealed ends. A one-tenth volume of 10X reaction buffer containing 300 mM Tris-HCl at pH 7.8, 100 mM MgCl₂, 100 mM DTT, 10 mM ATP, and 3 Weiss units of T4 DNA ligase (Promega Corp., Madison, WI) was added to each tube. The mixture was let stand overnight at room temperature. The following day an additional 1 Weiss unit of ligase was added to each tube and after 2 to 3 hours, the DNA was precipitated with one-tenth volume of 3 M sodium acetate (pH 5.2) and 2 volumes of 100% ethanol and dialyzed against TE (pH 8) for use in electroporation of electrocompetent E. coli DH5α cells.

Transformation of E. coli. Two methods were used for transforming E. coli. The first method involved transforming the ligation mixtures into electrocompetent cells of E. coli DH5α by electroporation using a GenePulser apparatus according to methods and instructions provided by the manufacturer (Bio-Rad Laboratories, Richmond, CA). Briefly, four 250-ml flasks of L broth were inoculated with 2.5 ml of an overnight culture of E. coli DH5α. The cultures were grown at 37°C until an OD₆₀₀ of 0.5 to 0.7 was reached. The flasks were chilled for 15 min on ice and the cells were harvested by centrifugation. The pellets were washed one time in 1 liter and one time in 500 ml of cold sterile distilled water. Finally, the pooled pellet was washed one time in 20 ml of cold 10% glycerol. The final pellet was resuspended in 200 μl of cold 10% glycerol. The suspended electrocompetent cells were dispensed into 40-μl samples. To each sample 2 to 3 μl of the precipitated/dialyzed ligation mixture was added. The mixture was transferred to a chilled 0.2-cm electroporation cuvette and pulsed one time at 2.5 kV, 25 μF, and 200 ohm resistance. One ml of SOC medium was immediately added to the cuvette and the cell suspension was transferred to a cotton-plugged culture tube. The cultures were incubated at 37°C with shaking for 1 h. They were then plated onto L agar containing 100 μg of ampicillin per ml and which had been spread 1 h before with 100 μl of 100 mM isopropylthio-β-D-galactoside (IPTG) and 40 μl of 2% 5-bromo-4-chloro-3-indolyl-β-D-galactoside (Xgal). The plates were incubated at 37°C for 16 to 20 h. The blue color was allowed to develop further at room temperature. The plasmids from the white Lac⁺ colonies were screened for possible inserts.

In the second method MAX efficiency or subcloning efficiency E. coli DH5α competent cells (Life Technologies, Inc., Gaithersburg, MD) were transformed with ligation mixtures according to a procedure described for each by the manufacturer. Transformants were plated and isolated as described above.

DNA sequencing and analysis. The sequences of cloned fragments of pXO1.1 (Weybridge A UM23) and pXO1 (Sterne) containing the junctions of the inverted segments were determined by the dideoxy chain termination method of Sanger et al. (19) using α-³²P dATP and the Sequenase ver. 1.0 sequencing kit (United States Biochemicals, Cleveland, OH). The sequencing reactions were performed according to the procedure described by the manufacturers. The fragments were cloned into pBluescriptIKS+ and the resulting constructs were used to obtain double stranded templates that were denatured prior to sequencing. The sequences were determined for both DNA strands of the cloned inserts. Whenever possible, M13 forward and reverse universal primers were used for sequencing.
Additional oligonucleotide primers obtained from Integrated DNA Technology (Coralville, IA) were used to extend the sequences of the cloned inserts. The sequences were then analyzed extensively using the University of Wisconsin Genetics Computer Group (GCG) software package.

RESULTS AND DISCUSSION

I. Physical and genetic analysis of the *B. anthracis* toxin plasmid pXO1

Our general approach to studying the physical and genetic characteristics of the *B. anthracis* toxin plasmid, as well as the capsule plasmid, has been to employ transposon mutagenesis to obtain insertion mutations in the plasmid and then to examine the resulting mutants for acquisition of new phenotypes. In previous reports (7, 8, 20, 21) our methodology for transposon mutagenesis and characteristics of some of the pXO1::Tn917 mutants have been described. In the Midterm Report (22) several of the insertion mutants were characterized further.

It should be recalled that Weybridge UM44 exhibited plasmid-derived phenotypic characteristics different from those observed in Weybridge A strains. Weybridge UM44 is a Trp" mutant which was isolated from the wild-type Weybridge strain, and Weybridge A was isolated from "wild-type" Weybridge as a mutant that grew much better than the parent strain on a minimal medium, minimal XO. The two strains, Weybridge UM44 and Weybridge A (and auxotrophs derived from the latter) differed in rate and extent of sporulation at 37°C, phage sensitivity, and growth characteristics on minimal medium. However, UM44-derived strains into which pXO1::Tn917 derivatives from UM23 were introduced showed characteristics similar to those typical of UM23. Because of differences observed in the toxin plasmid from the two strains, we have suggested that the plasmid of the wild-type Weybridge strain (and that from Weybridge UM44) be designated pXO1 and the one from Weybridge A strain be designated pXO1.1 (20).

The Midterm Report (22) documents the characterization of several pXO1::Tn917 insertion mutants of Weybridge A UM23 and describes the construction of a restriction map of pXO1.1 Tn917 inserted into a number of different sites on pXO1.1. Several insertion mutants exhibited characteristics similar to those of the Weybridge A UM23 parent strain. Mutant tp28 exhibited alterations in its sensitivity to bacteriophage CP-51. Several insertion mutants, including some deletants, exhibited alterations in toxin production. Two insertion mutants, tp29 and tp32, appeared to have interrupted a gene involved in positive regulation of toxin synthesis. Further examination of these two mutants led to the identification of a gene involved in positive activation of toxin synthesis (26). Another very interesting mutant, tp62, produced toxin components in the absence of bicarbonate. In this mutant Tn917 was determined to be located just upstream of the structural gene for lethal factor, suggesting that this region may be involved in negative regulation of toxin synthesis.
Quantitative analysis of toxin production by several insertions mutants. In the Midterm Report (22), results of two experiments examining toxin production by several insertion mutants grown in the absence of bicarbonate and horse serum were included. To provide more confidence in the values obtained for the amounts of toxin produced, a third experiment was performed with insertion mutants tp2A, tp21, tp29, tp32, tp39, tp62, and tp72 grown in the absence of bicarbonate and horse serum and the amounts of protective antigen (PA), lethal factor (LF), and edema factor (EF) in culture filtrates were determined as discussed previously (22). The averages of results from all three experiments are shown in Table 2 and standard error values are reported for those mutants producing toxin components in the absence of bicarbonate. The results confirmed that tp2A produced amounts of toxin components similar to those produced by the parent strain, Weybridge A UM23; tp21 did not produce detectable amounts of PA but, like UM23, it produced trace amounts of EF and LF; tp29, tp32, and tp39 were deficient in production of all three toxin components; tp62 overproduced the toxin components in the absence of bicarbonate; and tp72 was deficient in PA production (similar to tp21), but produced more LF than did UM23.

Analysis of altered BamHI-Sal fragments of pXO1.1::Tn917 deletion derivatives from UM23 tp21 and tp39. Based on results from restriction analyses of the pXO1.1::Tn917 deletion derivatives of UM23 tp21 and tp39, we determined that the origins of the 36- and 8.5-kb BamHI-Sal fragements of the plasmid from tp21 were the 34.8- and 13.9-kb BamHI fragments, respectively, and the 33- and 5.5-kb BamHI-Sal fragments of the plasmid from tp39 were the 34.8- and 7.4-kb BamHI fragments, respectively. To confirm these results, the altered BamHI-Sal fragments of the Tn917-tagged derivatives from tp21 and tp39 were isolated by electroelution and labelled with digoxigenin-labelled dUTP. Results of DNA-DNA hybridizations with BamHI-, PstI-, and EcoRI-digested pXO1 (Weybridge A UM23) using these isolated fragments as probes are shown in Table 3.

The 8.5-kb BamHI-Sal fragment of pXO1.1::Tn917 (tp21) hybridized to the 13.9-kb BamHI fragment, the 18.1-kb PstI fragment, and the 8.0- and 3.1-kb EcoRI fragments of pXO1 (Weybridge A UM23). The 36-kb BamHI-Sal fragment of the plasmid from tp21 hybridized to the 34.8-kb BamHI fragment, and the 9.3-, 6.6-, 6.3-, 5.2-, 2.8-, and 0.6-kb PstI fragments of pXO1 (Weybridge A UM23). Interestingly, the altered fragment did not hybridize to the 6.0-kb PstI fragment. Deletant tp21 had been shown previously to produce LF which suggested that at least a 1.4-kb portion of the 6.0-kb PstI fragment (determined from the lef sequence [2]) must be present since it contains the 3' end of the LF structural gene. A reasonable explanation might be that the presence of Tn917 sequences adjacent to this fragment interfered with the hybridization.

The 5.5-kb BamHI-Sal fragment of pXO1.1::Tn917 (tp39) hybridized to the 7.4-kb BamHI fragment, the 18.7- and 5.5-kb PstI fragments, and the 3.1- and 1.05-kb EcoRI fragments of pXO1 (Weybridge A UM23). Results from previous restriction analysis and DNA-DNA hybridization analysis with the cloned toxin structural genes suggested that the 3.1-kb EcoRI fragment that hybridized to the 5.5-kb BamHI-Sal fragment of the plasmid from tp39 is different from the 3.1-kb EcoRI fragment that hybridized to the 8.5-kb
BamHI-Sall fragment of the plasmid from tp21. The 33-kb BamHI-Sall fragment of the plasmid from tp39 hybridized to the 34.8-kb BamHI fragment, the 9.3-, 6.6-, 6.3-, 5.2-, 2.8-, and 0.6-kb PstI fragments of pXO1 (Weybridge A UM23). Again, this large BamHI-Sall fragment did not hybridize to the 6.0-kb PstI fragment. However, among the many EcoRI fragments that hybridized to the 33-kb fragment was an 0.8-kb fragment corresponding to the 0.8-kb EcoRI fragment in lef. Based on the sequence of lef (2), PstI should cut the 0.8-kb EcoRI fragment into two fragments 0.5 and 0.3 kb in size and the 0.5-kb PstI-EcoRI fragment should be homologous to the 6.0-kb PstI fragment. These observations suggested that at least a portion of the 6.0-kb PstI fragment must be present within the 33-kb BamHI-Sall fragment.

Attempts to Purify UM23 tp49 and tp71. Previously, we found discrepancies in the toxin phenotypes determined for deletants tp49 and tp71 from quantitative analysis of toxin production and DNA-DNA hybridizations of the digested pXO1.1::Tn917 deletion derivatives with the cloned toxin components. Quantitative analysis showed that tp49 and tp71 were PA+++, LF+, EF++ and PA++, LF++, EF+, respectively, while DNA-DNA hybridization analysis with the cloned toxin genes revealed that tp49 and tp71 should be PA+, LF+, EF and PA+, LF+, EF+, respectively. Plasmid profiles of tp49 and tp71 and results from restriction analysis of the plasmids from these mutants double digested with BamHI and Sall showed that the mutants contained multiple plasmid derivatives. We attempted first to isolate colonies containing the 40- and 47.8-kb plasmids from tp49 and tp71 spore stocks, respectively, by single colony isolations on L agar with inhibitory concentrations of erythromycin and lincomycin. After four rounds of single colony isolations, all isolates of tp49 and tp71 contained mixed populations of plasmids. Since the 40- and 47.8-kb plasmids of tp49 and tp71, respectively, were the predominant plasmids observed from plasmid extractions of cells grown in BHI broth containing 10% horse serum, isolates of tp49 and tp71 were grown in this medium prior to single colony isolations. Again all of the colonies isolated contained a mixed population of plasmids.

Finally, CP-51-mediated transduction was used in an attempt to transfer the 40- and 47.8-kb plasmids from these insertion mutants to Weybridge A UM23C1-2, a rifampicin-resistant derivative of the pXO1.1-cured strain UM23C1. The propagations were repeated four times and the transductions were repeated seven times with lysates from cultures of tp49 or tp71. No MLSR, Rif transductants were isolated that contained the small plasmid derivatives. These results suggested that the 40- and 47.8-kb plasmids from tp49 and tp71, respectively, may not be maintained stably within cells and that larger pXO1.1::Tn917 derivatives may provide factors necessary to stabilize these smaller plasmids.

Genetic analysis of atxA gene. Insertion mutants tp29 and tp32 are deficient in production of PA, LF, and EF and the Tn917 insertions within pXO1.1 from these two mutants were in the same fragment and outside of the toxin genes (8). These results suggested that Tn917 inserted within a region involved in positive activation of toxin synthesis. While we were involved in cloning the region of pXO1.1 containing the putative positive regulatory gene, I. Uchida, working in S. Leppla's laboratory at NIDR in Bethesda, MD, and taking advantage of information presented by Homung and Thome (8), cloned a gene involved in
positive activation of toxin synthesis. We provided evidence that the two laboratories cloned the same region of the plasmid. DNA-DNA hybridization analysis of digested pXO1.1 with the 1.3-kb HpaI-EcoRV fragment of Uchida's recombinant plasmid, plU51, containing the ORF involved in positive regulation of toxin synthesis, showed that the putative gene hybridized to the 13.9-kb BamHI fragment and the 18.1-kb PstI fragment of pXO1.1, fragments altered by Tn917 insertion in the plasmid derivatives from tp29 and tp32. To complete the project, the two laboratories collaborated and a gene, designated aMrA, encoding a trans-acting positive regulatory factor was identified. The cloned gene complemented the insertion mutations within tp29 and tp32. A paper describing the cloning and characterization of aMrA has been published (26).

The recombinant plasmid, plU68, containing the subcloned aMrA ORF was transferred to insertion mutants tp29 and tp32 to determine whether aMrA restored production of all three toxin components in these mutants and to some other strains to determine the effect of aMrA on toxin production. We tested the constructed strains for toxin production in CA-HEPES broth with and without sodium bicarbonate and horse serum. The averages of the results from two experiments are shown Table 4. Although the absolute values differed from those obtained by Uchida when he grew the strains in R medium in the presence or absence of sodium bicarbonate (26), the results confirmed that aMrA complements the insertion mutations in tp29 and tp32. These complemented mutants produced the three toxin components in the absence of sodium bicarbonate and horse serum. In the presence of sodium bicarbonate and horse serum, tp29(plU68) and tp32(plU68) produced amounts of toxin that were equivalent to or more than that produced by UM23-1, the streptomycin resistant isolate of UM23 used by Uchida for comparison of toxin synthesis. However, we observed that the parental strain of the insertion mutants, UM23, produced two to three times more PA and LF than did UM23-1. Thus, our results showed that the amounts of PA and LF produced by the complemented insertion mutants tp29 and tp32 were actually lower than those produced by the parental strain, a result that is usually expected in complementation studies.

Other results in Table 4 show that the aMrA gene product activated pag on plU71 in UM23C1-1. This provided supporting evidence that the aMrA gene product is a positive trans-acting factor. UM23-1(plU68) and UM23 tp62 (plU68) grew poorly under the conditions used for toxin synthesis.

To provide more evidence that the product of aMrA is a trans-acting positive regulator, the ca. 10-kb tetracycline-resistance recombinant plasmid, plU51, containing cloned aMrA was introduced by electroporation into deletant UM23 tp39, a mutant deficient in production of all three toxin components and whose plasmid contains deletions encompassing pag, cya, and aMrA, but not lef. Two electrotransformants, UM23 tp39 ef3 and ef5, were isolated and the plasmids from these transformants were examined by agarose gel electrophoresis. These electrotransformants contained a plasmid comigrating with pXO1::Tn917 from tp39 and a plasmid comigrating with plU51.
UM23 tp39 etf3 and etf5 were analyzed for production of PA, LF, and EF by quantitative methods described previously and the results are shown in Table 5. Plasmid plU51 was not maintained stably in the tp39 transformants unless they were grown under selection with tetracycline. When tp39 etf3 and etf5 were grown in CA-HEPES (pH 7.5) in the presence of added bicarbonate, horse serum, and inhibitory concentrations of tetracycline, LF was produced. However, the concentration of LF was about five- to ten-fold lower than that observed for UM23. No detectable amounts of PA or EF were present in the culture filtrates. Since abxA was deleted from pXO1::Tn917 (tp39), then complementation of LF production by plU51 provided evidence that abxA encodes a trans-acting positive activator. Although complementation of tp39 with cloned abxA did occur, the concentrations of LF in the culture filtrates of etf3 and etf5 was much lower than anticipated. Thus, the optimal conditions for LF production by the electrotransformants may not have been attained in broth cultures under the conditions tested. Also, other genes may have been deleted from the plasmid of tp39 that are involved in regulating toxin synthesis.

II. Analysis of an Inversion Encompassing the Toxin-Encoding Region of pXO1.1 (Weybridge A) and pXO1 (Sterne)

The Midterm Report (22) presented evidence that the order of the toxin genes on pXO1 from a Sterne strain obtained from USAMRIID is reversed from that of the same genes on pXO1.1 carried by the Weybridge A strain. The evidence available at that time suggested that an inversion had occurred in the toxin-encoding region of one of the plasmids. This evidence is summarized below and is then followed by results of further experiments which show conclusively that an inversion had occurred.

The main experimental points of evidence reported in the Midterm Report can be summarized as follows (refer to that report [22] for details and tabular and graphical data):

1. The BamHI and PstI restriction profiles of pXO1.1 from B. anthracis Weybridge A UM23 as determined in our laboratory differed from those published by Robertson et al. (15) for pXO1 from a different pXO1+, pXO2- strain (labeled Sterne). The difference was observed in the region surrounding the toxin structural genes (8). The 29-kb and 19-kb BamHI fragments shown on the restriction map of pXO1 constructed by Robertson et al. differed from the 34.8-kb and 14.6-kb fragments generated by BamHI digestion of pXO1.1.

Double digestion of pXO1.1 with BamHI and SalI showed a restriction profile which differed from that deduced from Robertson's map. Three SalI restriction sites were observed in pXO1.1. They are located in the 38.7-kb 19.9-kb and 14.6-kb BamHI fragments and corresponded to those in the 37-kb, 20-kb, and 29-kb BamHI fragments on Robertson's map, respectively. These results suggested that the 14.6-kb fragment of pXO1.1 was homologous to the 29-kb fragment of pXO1 (Robertson).

2. In addition to the differences observed for the BamHI restriction profiles, PstI digestion of pXO1.1 generated an 18.7-kb and a 9.3-kb fragment instead of a 20-kb and an 8.6-kb fragment depicted on
Robertson's map. Results from homologous DNA-DNA hybridizations showed that the 9.3-kb as well as the 6.6-kb, 6.3-kb, 6.0-kb, and 5.2-kb Pstl fragments from pXO1.1 were nested within the 34.8-kb BamHl fragment. DNA-DNA hybridization studies using the cloned toxin structural genes as well as secondary digestion of the 34.8-kb fragment provided evidence that the Pstl fragments homologous with the BamHl fragment are the five fragments listed above. DNA-DNA hybridizations of digested pXO1.1 with the cloned LF structural gene showed that it hybridized to the 34.8-kb BamHl fragment and to the 6.6-kb and 6.0-kb Pstl fragments. According to Robertson's map ***lef*** is located on the 6.6-kb and 6.0-kb Pstl fragments which are nested within the 29-kb BamHl fragment. Robertson's map also shows that the 19-kb BamHl fragment contains Pstl fragments which may correspond to the 9.3-kb, 6.3-kb, and 5.2-kb Pstl fragments located within the 34.8-kb BamHl fragment of pXO1.1. These results suggested that the 34.8-kb BamHl of pXO1.1 shares homology with the 29-kb and 19-kb BamHl fragments of pXO1 from Robertson's strain.

(3) The evidence presented above suggested that the region encompassing the toxin structural genes in pXO1.1 from Weybridge A UM23 may be inverted in comparison to the toxin-encoding region shown on the restriction map of pXO1 constructed by Robertson et al. (15). The orientation of the region encoding the toxin structural genes has been designated as α for pXO1 from Robertson's *B. anthracis* strain and as β for pXO1.1 from Weybridge A UM23 (23).

The restriction profiles for pXO1 isolated from other *B. anthracis* (pXO1⁺, pXO2) strains, including Weybridge, Weybridge A, Weybridge B, Sterne (USAMRIID), Anvax, V770, PM36-R1, Ames ANR-1, and New Hampshire NNR-1, were examined (8). All except Sterne (USAMRIID) exhibited restriction profiles similar to the profiles exhibited by pXO1.1 from Weybridge A UM23 and therefore, all most likely carry the toxin-encoding region in the β orientation. The toxin plasmid from Sterne (USAMRIID) generated BamHl, BamHl-SalI, and Pstl restriction patterns which corresponded to those shown for pXO1 by Robertson, suggesting that the toxin-encoding region of pXO1 from Sterne (USAMRIID) is most likely in the α orientation. The origin of the Sterne strain used by Robertson et al. (15) has not been determined; however, it seems likely that the strain he used is the same as the Sterne (USAMRIID) strain.

(4) By a series of restriction analyses and DNA-DNA hybridization tests the locations of the ends of the inverted segment were approximated (22). Then to provide evidence that an inversion had occurred within the toxin-encoding region, restriction fragments encompassing the ends of the inverted segment were used in DNA-DNA hybridizations to probe the BamHl- and Pstl-digested plasmids from Sterne (USAMRIID) and from Weybridge A UM23. The results of these experiments confirmed that an inversion involving a segment of pXO1 as large as 40 kb had occurred.

Since the Midterm Report was prepared further experiments, reported below, have been carried out to confirm that an inversion had occurred. These experiments include cloning the junction fragments and determining their DNA sequences.

**Restriction analyses of pXO1 from several *B. anthracis* strains.** Previously, the BamHl restriction patterns of pXO1 from Weybridge, Weybridge UM44-1, Weybridge B, Anvax, PM36-R1, and Vollum V770...
were similar to that obtained for pXO1.1 from Weybridge A UM23 and different from that obtained for pXO1 from Sterne (6, 8, 22). All of the plasmids except pXO1 (Sterne) contain a 34.8- and 14.6-kb BamHI fragment instead of a 29- and 19.5-kb BamHI fragment found in pXO1 (Sterne). These results provided evidence that the toxin-encoding regions of pXO1 from the former strains existed in the same orientation as that observed for pXO1.1 from Weybridge A UM23, but lie in opposite orientation to that observed for pXO1 from Sterne. To provide more evidence supporting this hypothesis, we compared the PstI and EcoRI restriction patterns of pXO1 from the various B. anthracis strains with those of pXO1.1 (Weybridge A UM23) and pXO1 (Sterne).

The results of the restriction analyses showed that pXO1 from Weybridge, Weybridge UM44-1, Weybridge B, Anvax, PM36-R1, and Vollum V770 contained the 18.7- and 9.3-kb PstI fragments and the 5.4- and 2.4-kb EcoRI fragments, fragments comigrating with the PstI and EcoRI fragments containing the junctions of the inverted toxin-encoding region of pXO1.1 (Weybridge A UM23). Only pXO1 (Sterne) contained the 19- and 8.6-kb PstI junction fragments and the 4.8- and 3.1-kb EcoRI junction fragments. Thus, the orientation of the toxin-encoding region of pXO1 from the various B. anthracis kept in our laboratory appears to be the same as that for pXO1.1 from Weybridge A UM23 (referred to as \( \beta \) orientation).

Other differences were observed in the PstI and EcoRI patterns of pXO1 from the various B. anthracis strains. The toxin plasmid from Weybridge was shown previously to contain an extra 10-kb BamHI fragment. The PstI restriction pattern of pXO1 (Weybridge) revealed an extra 6.3- and 2.9-kb fragment. The EcoRI restriction pattern was more difficult to interpret; however, pXO1 appears to contain extra fragments approx. 4.5 and 1.2 kb in size. Although no differences were observed for the BamHI restriction profiles of pXO1 from Weybridge A UM23, Weybridge UM44-1, PM36-R1, and Vollum V770, we observed differences in the EcoRI and PstI restriction patterns. The toxin plasmids from PM36-R1 and Vollum V770 were missing a ca. 7.2-kb EcoRI fragment observed in pXO1 from Weybridge derivatives, Anvax, and Sterne and there appeared to be an extra fragment approx. 7.4 kb in size. No differences were observed in the PstI restriction profiles of the two former plasmids in comparison to that of pXO1.1 (Weybridge A UM23). These results suggested that pXO1 from PM36-R1 and Vollum V770 may contain approx. 0.2 kb of extra DNA. If the extra DNA is in the larger PstI or BamHI fragments, then the differences in migration of the fragments in an agarose gel may not be detected. The toxin plasmid from Weybridge UM44-1 contains an extra PstI fragment approx. 4.1 kb in size and extra EcoRI fragments approx. 2.9 and 1.2 kb in size. The origins or locations of these extra pieces of DNA observed in pXO1 from Weybridge, Weybridge UM44-1, PM36-R1, and Vollum V770 have not been determined.

Analysis of the PstI restriction map of the 34.8-kb BamHI fragment of pXO1.1 (Weybridge A UM23). As reported in the Midterm Report (22), BamHI, BamHI-SalI, and PstI restriction maps had been constructed for a 77-kb region of pXO1.1 (Weybridge A UM23) encompassing the toxin structural genes. Results from DNA-DNA hybridization analysis with the altered 34.8-kb BamHI-SalI fragments of
pXO1.1::Tn917 from tp21 and tp39 showed that the large BamHI fragments hybridized to a 2.8- and 0.6-kb PstI fragment not observed in previous restriction analyses.

Since the earlier analyses of the 34.8-kb BamHI fragment were done, we have made improvements in electroelution methods that have increased the yield of large restriction fragments and in Southern transfer techniques that have increased the amount of smaller fragments adhering to the nylon membrane. Thus, restriction analysis and DNA-DNA hybridization analysis could be used with greater confidence to confirm whether the 0.6-kb and 2.8-kb PstI fragments were contained within the 34.8-kb BamHI fragment and to determine the location of these fragments within the large BamHI fragment. The 34.8-kb BamHI fragment was isolated from pXO1.1::Tn917 (tp1A) by electroelution. The plasmid derivative from tp1A contains Tn917 within the 38.7-kb BamHI fragment which causes this altered fragment to migrate much slower than the 34.8-kb fragment in a 0.3% agarose gel, allowing better separation of the two large fragments. Because contamination of the 34.8-kb fragment with the 38.7-kb fragment has been a problem in the past, a much cleaner preparation of the 34.8-kb fragment could be isolated from pXO1.1::Tn917 (tp1A). The 34.8-kb BamHI fragment was digested with PstI and the restriction pattern was determined by agarose gel electrophoresis. The 34.8-kb BamHI fragment was shown to contain a 9.3-, 6.6-, 6.3-, 5.2-, 4.5-, 0.6-, and 0.3-kb PstI fragment. As determined from the sequence of pag (30), the 6.0-kb PstI fragment which contains pag should have a BamHI site generating two fragments approx. 1.5 kb and 4.5 kb in size. Based on this information, the 4.5-kb fragment observed above should correspond to the 6.0-kb PstI fragment. Thus, the 0.3-kb fragment should be part of the 2.8-kb PstI fragment.

Restriction analysis of the small plasmid derivative of tp71 was used to determine whether the 0.3-kb fragment found in the 34.8-kb BamHI fragment was part of the 2.8-kb PstI fragment. Previous restriction analyses of the small plasmid derivative of tp71 showed that the plasmid had two BamHI sites, generating an intact 34.8-kb fragment and a 13.9-kb fragment which contained Tn917. Restriction analysis also showed that the plasmid contained a 16-, 9.3-, 6.6-, 6.3-, 5.2-, 2.8-, and 0.6-kb PstI fragment. The 2.8-kb PstI fragment should be within one of the two BamHI fragments of this plasmid. The 13.9-kb BamHI fragment was isolated and digested with PstI. Restriction analysis showed that an 11-kb and a 2.6-kb fragment were located within this BamHI fragment. These results suggested that the 2.8-kb PstI fragment contained a BamHI restriction site generating a junction fragment approx. 0.2 to 0.3 kb in size corresponding to the end of the 34.8-kb BamHI fragment.

To determine the location of the 0.6-kb PstI fragment within the 34.8-kb BamHI fragment, the 9.8-kb BamHI-Sall fragment of pXO1::Tn917 (tp36) was digested with PstI. The insertion of Tn917 within the plasmid derivative from tp36 has been shown to be within the 6.3-kb PstI fragment. Sall digestion of the Tn917-containing BamHI fragment generates two BamHI-Sall fragments approx. 33 and 9.8 kb in size. The PstI restriction pattern of the 9.8-kb BamHI-Sall fragment showed that a ca. 9.0-kb fragment corresponding to the altered 6.3-kb PstI fragment and a 0.6-kb fragment were observed. To confirm these results, the 9.8-kb fragment was labelled with digoxigenin-labelled dUTP and used in DNA-DNA hybridizations with BamHI-
and PstI-digested pXO1.1 (Weybridge A UM23). The 9.8-kb fragment hybridized to the 34.8-kb BamHI fragment and the 6.3-, 2.8-, and 0.6-kb PstI fragments. In addition, previous restriction analysis of the Tn917-tagged plasmids from tp2A and tp36 showed that the Tn917 insertions were within the same 1.1-kb EcoRI fragment within the 34.8-kb BamHI fragment and the locations of the insertions were approx. 0.1 kb apart (discussed below). Tn917 was also shown to have inserted within the 5.2-kb PstI fragment of the plasmid from tp2A and the 6.3-kb PstI fragment of the plasmid from tp36. These results suggested that the 0.6-kb PstI fragment was not located between the 5.2-kb and 6.3-kb PstI fragments, but that it was located between the 6.3-kb and 2.8-kb PstI fragments. The order of the PstI fragments within the 34.8-kb BamHI fragment is shown in Fig. 1.

EcoRI restriction mapping of pXO1.1 (Weybridge A). The EcoRI restriction map of pXO1.1 (Weybridge A UM23) was constructed to obtain a more precise location of the junction fragments of the inverted segment. The locations of many of the EcoRI fragments between the 5.6-kb fragment containing a portion of lef and the 3.1-kb fragment located upstream of cya, as shown in Fig. 1, were determined from DNA-DNA hybridization analyses with the cloned toxin structural genes. In addition the locations of the EcoRI restriction sites within the toxin structural genes were extrapolated from the sequences of each of these genes (2, 16, 30).

Based on restriction analysis of the Tn917-tagged deletion derivatives of tp21 and tp39, the deleted 5.6- and 3.1-kb EcoRI fragments were determined to be nested within the 13.9-kb BamHI fragment. As shown in Table 3, the 8.5-kb BamHI-SalI fragment of pXO1.1::Tn917 (tp21) hybridized to the 8.0- and 3.1-kb EcoRI fragments, suggesting that the 3.1-kb fragment lies adjacent to the 8.0-kb EcoRI fragment and the 5.6-kb fragment lies between the 3.1- and 6.2-kb EcoRI fragments (Fig. 1).

Restriction analysis was used to identify and localize the EcoRI restriction sites within the 14.6-kb BamHI fragment. To obtain a preparation of the 14.6-kb fragment that was relatively free of the closely migrating 13.9-kb fragment, the 14.6-kb BamHI fragment was isolated from pXO1.1::Tn917 (tp29), a plasmid derivative containing Tn917 within the 13.9-kb BamHI fragment. The 14.6-kb fragment was digested with EcoRI or ClaI or double digested with both of these enzymes. The restriction digestion of the 14.6-kb fragment is shown in Table 6 and the probable location of the restriction sites are depicted in Fig. 2 (below Table 6). As will be discussed below, the 5.4-kb EcoRI fragment containing a junction of the inversion is cut by ClaI, generating two fragments approx. 4.0 and 1.5 kb in size. Based on the locations of the 8.0-, 3.1-, and 1.05-kb EcoRI fragments within the 7.4-kb BamHI fragment, the 3.1-kb EcoRI fragment (not to be confused with the 3.1-kb fragment lying downstream of cya, Fig.1) should contain a BamHI site generating a 1.8- and 1.3-kb BamHI-EcoRI fragment. The 1.3-kb BamHI-EcoRI fragment should be the junction fragment of the 14.6-kb BamHI fragment. As shown in Fig. 2, the results from the digestion of the 14.6-kb BamHI fragment with EcoRI and ClaI suggested that the 5.4-kb fragment lies adjacent to the 3.1-kb EcoRI fragment (shown as the 1.3-kb BamHI-EcoRI fragment). Since the 4.2-kb EcoRI fragment
does not contain a CiaI site, then it must be adjacent to the 5.4-kb EcoRI fragment. The origin of the 3.2-
kb BamHI-EcoRI junction fragment has not been determined.

With the exception of the 5.6-, 5.4-, and 0.8-kb EcoRI fragments which hybridized to lef, the
locations of EcoRI restriction sites within the 34.8-kb BamHI fragment of pXO1.1 (Weybridge A UM23) were
determined by restriction analyses and DNA-DNA hybridization analyses. The EcoRI restriction pattern
within the 9.3-kb PstI fragment was determined for the cloned 9.3-kb fragment of pJMH28. Insertion
mutants, UM23 tp2A, tp36, and tp62, have Tn917 insertions in various locations within the 34.8-kb BamHI
fragment. SaI which cleaves within Tn917 but not within the 34.8-kb fragment has allowed the isolation of
various regions of the large BamHI fragment that can be used for further analysis. To determine the size of
the EcoRI restriction fragment between the LF structural gene and the 9.3-kb PstI fragment, the lef-
containing 15-kb BamHI-SaI fragment of the plasmid derivative from tp62 was digested with EcoRI and the
results are listed in Table 7. EcoRI digestion of the 15-kb BamHI-SaI fragment generated 5.6-, 4.0-, 3.3-, 0.8-, and 0.72-kb fragments. Based on the sequence of pag (30), we deduced that the 5.4-kb EcoRI
fragment which contains the 3' end of the PA structural gene as well as the 3' end of the LF structural gene
contains a BamHI site, generating two fragments approx. 3.9 and 1.5 kb in size. Thus, the 4.0-kb fragment
observed in the 15-kb BamHI-SaI fragment is most likely part of the 5.4-kb EcoRI fragment. The 5.6- and
0.8-kb EcoRI fragments corresponded to the other fragments that hybridized to the lef probe. As
discussed previously, the location of the Tn917 insertion within the plasmid derivative from tp62 was 0.7 kb
within the 9.3-kb PstI fragment (22). Restriction analysis of this fragment from pJMH28 showed that the
EcoRI restriction site of the 1.2-kb EcoRI fragment is located near the PstI restriction site of the 9.3-kb
fragment near the site of Tn917 insertion. Therefore, the 3.3-kb fragment should correspond to the 2.7-kb
SaI arm of Tn917 plus a 0.7-kb region of the 1.2-kb EcoRI fragment. From these results, the location of
the 0.72-kb fragment was determined to be between the 5.6-kb and 1.2-kb EcoRI fragments. The locations
of these fragments are depicted in Fig. 1.

The locations of the EcoRI restriction sites to the right of the 2.4-kb EcoRI fragment within the 34.8-
kB BamHI fragment and the 9.3-kb PstI fragment, shown in Fig. 1, were determined by restriction analysis
of the 24-kb BamHI-SaI fragment of the plasmid from tp62 and the 9.8-kb BamHI-SaI fragments of the
plasmids from UM23 tp2A and tp36. The results of these restriction analyses are summarized in Table 7.
Digestion of all three of the BamHI-SaI fragments with EcoRI generated some fragments that do not
correspond to EcoRI fragments of wild-type pXO1.1 (Weybridge A UM23). Fragments approx. 3.1 or 3.2 kb
in size were observed in all three of the BamHI-SaI fragments that corresponded to SaI digestion of a
Tn917-containing EcoRI fragment. Digestion of the Tn917-containing 6.8-kb EcoRI fragment (1.2-kb EcoRI
fragment plus Tn917 [5.6 kb]) of the plasmid derivative from tp62 with SaI generated an EcoRI-SaI
fragment in the 24-kb BamHI-SaI fragment that is approx. 3.1 kb in size. Similarly, digestion of the Tn917-
containing 6.7-kb EcoRI fragments (1.1-kb EcoRI fragment plus Tn917 [5.6 kb]) of the plasmid derivatives
from tp2A and tp36 with SaI generated EcoRI-SaI fragments in each of the 9.8-kb BamHI-SaI fragments

-20-
that are approx. 3.2 and 3.1 kb in size, respectively. These results provided evidence that the Tn917 insertions in the plasmids from tp2A and tp36 are approx. 0.1 kb apart.

A 2.1- to 2.2-kb fragment was observed when the BamHI-SaII fragments of the plasmid derivatives from UM23 tp2A, tp36, and tp62 were digested with EcoRI. Since these fragments do not correspond to any EcoRI fragments of wild-type pXO1 (Weybridge A UM23), they are most likely the EcoRI-BamHI junction fragments. Thus, results from digestion of the 9.8-kb BamHI-SaII fragments of the plasmids from tp2A and tp36 suggested that the 4.3-kb EcoRI fragment is adjacent to the 2.2-kb junction fragment and the 1.1-kb EcoRI fragment is adjacent to the 4.3-kb EcoRI fragment. The origin of the 2.2-kb junction fragment has not been confirmed; however, results from DNA-DNA hybridization of EcoRI-digested pXO1 (Weybridge A UM23 or Sterne) with the digoxigenin-labelled 9.8-kb BamHI-SaII fragment of the plasmid derivative from tp36 suggested that the junction fragment may correspond to a 7.0-kb EcoRI fragment.

The EcoRI fragments generated by EcoRI digestion of the 24-kb BamHI-SaII fragment of pXO1::Tn917 (UM23 tp62) were 7.3, 4.3, 3.1, 2.4, 2.1, 1.9, 1.1, 0.75, and 0.7 kb in size (Table 7). The locations of the 4.3-, 3.1-, 2.1-, and 1.1-kb fragments were discussed above. The locations of the 2.4-, 1.9-, 0.75- (rounded off to 0.8 in Fig. 1), and 0.7-kb EcoRI fragments were determined by restriction analysis of the 9.3-kb insert of pJMH28. By process of elimination, the 7.3-kb EcoRI fragment must be located between the 2.4- and 1.1-kb EcoRI fragments. The order of the EcoRI fragments within the 34.8-kb BamHI fragment is shown in Fig. 1.

Cloning of the EcoRI fragments of pXO1.1 (Weybridge A) and pXO1 (Sterne) encompassing the junctions of the Inverted segment. The restriction patterns of EcoRI-digested pXO1 (Sterne) and pXO1.1 (Weybridge A UM23) showed that pXO1 from Sterne contained 3.1- and 4.8-kb EcoRI fragments differing from the 2.4- and 5.4-kb EcoRI fragments found in pXO1.1 from Weybridge A UM23 (9). These observations suggested that these EcoRI fragments of pXO1.1 (Weybridge A UM23) and pXO1 (Sterne) contain the junctions of the inverted segment. Since most of the EcoRI fragments existed as doublets or triplets, we decided to shotgun clone the EcoRI restriction fragments and isolate the cloned fragments of interest. The regions of the agarose gel containing the 3.1- and 4.8-kb EcoRI fragments from pXO1 (Sterne) and the 2.4- and 5.4-kb EcoRI fragments from pXO1.1 (Weybridge A UM23) were gel purified and ligated into pBluescriptIIKS(+). The ligation mixture was introduced into MAX efficiency E. coli DH5α competent cells by transformation.

Recombinant plasmids containing the 3.1-kb EcoRI fragment from pXO1 (Sterne) and the 2.4-kb EcoRI fragment from pXO1.1 (Weybridge A UM23) were isolated based on similarities in the Clal, SstI, and HindIII restriction patterns. Two transformants containing recombinant plasmids carrying a 3.1-kb and a 2.4-kb EcoRI fragment were isolated and constructs were designated pJMH4 and pJMH5. Partial restriction maps of pJMH4 and pJMH5 with Clal, HindIII, SstI, and EcoRI are shown in Fig. 3. The 2.4-kb EcoRI insert contained a Clal-EcoRI fragment approx. 0.8 kb in size which differed from the 1.5-kb Clal-EcoRI fragment found in the 3.1-kb EcoRI insen. The difference of 0.7 kb in the sizes of the Clal-EcoRI
fragments corresponded to the difference in the sizes of the two EcoRI fragments. The CiaI-EcoRI fragments of the two EcoRI inserts are depicted above the crosshatched boxes in Fig. 3.

Recombinant plasmids containing the 4.8-kb EcoRI fragment from pXO1 (Sterne) and the 5.4-kb EcoRI fragment from pXO1.1 (Weybridge A UM23) were isolated based on results from DNA-DNA hybridization analysis using digoxigenin-labelled 19-kb PstI fragment from pXO1 (Sterne) as a probe. Restriction analysis of the cloned 9.3-kb PstI fragment from pXO1.1 (Weybridge A UM23) showed that the 2.4-kb EcoRI fragment is nested within the 9.3-kb PstI fragment. As discussed previously, the 9.3-kb PstI fragment shares homology with the 8.6-kb PstI fragment of pXO1 from Sterne (8922). Since the 2.4-kb fragment showed similarities in restriction patterns to those of the 3.1-kb EcoRI fragment of pXO1 (Sterne), then the 3.1-kb fragment must be nested within the 8.6-kb PstI fragment of pXO1 (Sterne). Thus, the 4.8-kb EcoRI fragment should be nested within the 19-kb PstI fragment of pXO1 (Sterne) and should share homology with the 5.4-kb EcoRI fragment from pXO1.1 (Weybridge A UM23).

The 19-kb PstI fragment of pXO1 (Sterne) hybridized to a recombinant plasmid containing a 4.8-kb EcoRI insert designated pJMH10 and to one recombinant plasmid containing a 5.4-kb insert designated pJMH9. As shown in Fig. 3, the locations of the AvaI, HindIII, EcoRV, and KpnI restriction sites were similar for each insert. Similar to the 2.4- and 3.1-kb EcoRI inserts, the 5.4- and 4.8-kb EcoRI inserts contained a 1.5-kb and a 0.8-kb CiaI-EcoRI fragment, respectively, corresponding to the differences in the sizes of the two inserts (see region of pJMH9 and pJMH10 above crosshatched boxes in Fig. 3). Interestingly, these results suggested that the 1.5-kb CiaI-EcoRI fragment of the 3.1-kb EcoRI fragment of pXO1 (Sterne) may be homologous to that of the 5.4-kb EcoRI fragment of pXO1.1 (Weybridge A UM23) and the 0.8-kb CiaI-EcoRI fragment of the 4.8-kb EcoRI fragment of pXO1 (Sterne) may be homologous to that of the 2.4-kb EcoRI fragment of pXO1.1 (Weybridge A UM23).

Subcloning of the cloned EcoRI fragments of pXO1.1 (Weybridge A) and pXO1 (Sterne) containing the junctions of the Inverted segment. Although pXO1 (Sterne) and pXO1.1 (Weybridge A UM23) exhibited differences in PstI, BamHI, and EcoRI restriction patterns, no differences were observed in the CiaI restriction patterns of these plasmids (data not shown). The difference in the CiaI-EcoRI fragments of the 2.4-kb and 3.1-kb inserts and of the 5.4-kb and 4.8-kb inserts suggested that the inversion occurred at or near the CiaI restriction site. To isolate smaller fragments containing the junctions of the inverted toxin-encoded region of pXO1, the 1.0-kb HindIII fragment of pJMH4, the 1.7-kb HindIII fragment of pJMH5, the 2.7-kb KpnI fragment of pJMH9, and the 1.9-kb KpnI fragment of pJMH10 (depicted by the crosshatched boxes in Fig. 3) were subcloned into pBluescriptIIKS(+) . The orientation of the inserts was determined by restriction analysis with CiaI. Transformants were isolated containing recombinant plasmids carrying each of the subcloned fragments in either orientation and the recombinant plasmids were designated pJMH12 to pJMH26. Partial restriction maps of pJMH12, pJMH16, pJMH20, and pJMH24 are shown in Fig. 4.
DNA-DNA hybridization analysis of pXO1.1 (Weybridge A) and pXO1 (Sterne) with the cloned junction fragments of the inverted toxin-encoding region. To confirm that the junctions of the inverted segment in each plasmid had been cloned, the 2.7-kb KpnI fragment of pJMH12 and the 1.0-kb HindIII fragment of pJMH24 that originated from the 5.4-kb and 2.4-kb EcoRI fragments of pXO1.1 (Weybridge A UM23), respectively, as well as the 1.9-kb KpnI fragment of pJMH16 and the 1.7-kb HindIII fragment of pJMH20 that originated from the 4.8-kb and 3.1-kb EcoRI fragments of pXO1 (Sterne), respectively, were used in DNA-DNA hybridizations of BamHI-, PstI-, and EcoRI-digested pXO1.1 from Weybridge A UM23 and pXO1 from Sterne under high stringency conditions. The results of these hybridization experiments are shown in Table 8. As depicted in Fig. 5, the junctions of the inverted segment in pXO1.1 (Weybridge A UM23) are contained within the 34.8- and 14.6-kb BamHI fragments, the 18.7- and 9.3-kb PstI fragments, and the 5.4- and 2.4-kb EcoRI fragments. Likewise, the junctions of the inverted segment in pXO1 (Sterne) are contained within the 29- and 19.5-kb BamHI fragments, the 19- and 8.6-kb PstI fragments, and the 4.8- and 3.1-kb EcoRI fragments.

As expected, each subcloned fragment originating from one pXO1 plasmid hybridized to the two restriction fragments of the other pXO1 plasmid containing the junctions of the inverted segment. For example, the 2.7-kb KpnI fragment of the 5.4-kb EcoRI fragment of pXO1.1 (Weybridge A UM23) hybridized to the 4.8- and the 3.1-kb EcoRI fragments of pXO1 (Sterne) because the 2.7-kb fragment contains regions that are homologous to both EcoRI fragments of pXO1 (Sterne). In addition, each subcloned fragment not only hybridized to the EcoRI fragment from which it originated, but also hybridized to the EcoRI fragment of the same plasmid containing the other junction of the inverted toxin-encoding region. In the example above, the 2.7-kb KpnI fragment hybridized not only to the 5.4-kb EcoRI fragment of pXO1.1 (Weybridge A UM23), but it also hybridized to the 2.4-kb EcoRI fragment of the same plasmid. These results suggested that the ends of the inverted segment encompassing the toxin genes may be inverted repeats. Because of the high stringency conditions used in the hybridizations, these results also suggested that the sequences of the inverted repeats may be a perfect or near perfect match.

Determination and analysis of the sequences of the cloned junctions fragments of the inverted segments of pXO1.1 (Weybridge A) and pXO1 (Sterne). The sequencing strategies for determining the sequences of the cloned junction fragments of the inverted segments of pXO1.1 (Weybridge A UM23) and pXO1 (Sterne) are shown in Fig. 6. The cloned inserts of pJMH28 (9.3-kb PstI insert containing WeyAR), pJMH4 (2.4-kb EcoRI insert, WeyAR), and pJMH5 (3.1-kb EcoRI insert, SterneR) and the subcloned inserts of pJMH12 (WeyAL), pJMH24 (WeyAR), pJMH16 (SterneL), and pJMH20 (SterneR) were sequenced using the dideoxy chain termination method of Sanger et al. (19). Synthetic oligonucleotide primers were used to extend the sequence of each of the cloned inserts. The letter "L" or "R" is attached to the cloned fragment designation, i.e. WeyAL, to represent the left or right inverted repeat flanking the toxin-encoding region of pXO1 as depicted in Fig. 5. WeyAL and WeyAR originated from the 5.4- and 2.4-kb EcoRI
fragments of pXO1 (Weybridge A), respectively, and SterneL and SterneR originated from the 4.8- and 3.1-kb EcoRI fragments of pXO1 (Sterne), respectively.

The sequences obtained for the junction fragments are shown in Figs. 7 to 10. In all instances, the sequence begins at or near the EcoRI restriction site and proceed past the ClaI restriction site. The sequences were determined for both strands and analyzed by thePILEUP and Bestfit programs of the GCG package software. We found that the ends of the inverted segments of pXO1.1 (Weybridge A UM23) and pXO1 (Sterne) are flanked by imperfect 1336-bp inverted repeats. As shown in Fig. 11, the results of the Bestfit of the sequences of WeyAL and WeyAR revealed several basepair mismatches and deletions. A 68-bp gap was discovered in the sequence of WeyAL inverted repeats. Analysis of the sequence of WeyAR inverted repeat (nt1168 to nt1236, Fig. 11) revealed a direct repeat sequence. Recombination of these direct repeats may have resulted in the 68-bp deletion in the WeyAL inverted repeat. A 13-bp gap was observed in the WeyAR inverted repeat corresponding to nt1930 to nt1942 in WeyAL inverted repeat. Analysis of the sequences at the ends of each of WeyAL and WeyAR revealed an imperfect 19-bp inverted repeat in WeyAR and an imperfect 28-bp inverted repeat in WeyAL (shown in Figs. 3, 4, and 7). The 19-bp inverted repeats of WeyAR are deletion derivatives of the 28-bp inverted repeats of WeyAL. These results suggest that WeyAL and WeyAR may be IS elements; however no target duplications were observed in the sequence.

As shown in Fig. 12, a Bestfit analysis of the sequences of SterneL and SterneR inverted repeats revealed similarities in the basepair mismatches and deletions observed for WeyAL and WeyAR shown in Fig. 11. The analysis of the patterns of the mismatches and deletions within the sequences of WeyAL, WeyAR, SterneL, and SterneR provided evidence that the inversion occurred within the inverted repeats at or near the ClaI restriction sites. A probable site of the inversion is illustrated in Fig. 13. The imperfect 19-bp inverted repeat shown for WeyAR was found at the ends of SterneR (Fig. 8, 10). Similar to WeyAL, SterneL may have the imperfect 28-bp inverted repeats at both ends (depicted in Fig. 9); however, the complete sequence for the right 28-bp inverted repeat (see Fig. 6 and beginning of Fig. 9) was not determined because no fragment within this region of pXO1 (Sterne) had been cloned.

The sequences of the four cloned junction fragments were analyzed with the Frames program of the GCG package to determine the location of any ORFs. The locations of the ORFs as well as the directions of transcription are shown in Fig. 14. Two major ORFs (ORF1 and ORF2) exist in WeyAR, ORF1 exists in SterneL, a shorter ORF1 exists in WeyAL, and ORF2 and a shorter ORF1 exist in SterneR. The beginnings and ends of the ORFs are also shown in Figs. 7 to 10. ORF1 appears to code for the same protein in all instances except that ORF1 terminated earlier in WeyAL and SterneR because of a frameshift mutation caused by the deletion of a T (nt535 WeyAR and nt286 SterneR, Fig. 11 and 12). Thus, ORF1 in WeyAR and SterneL is approx. 822 bp in size and may encode a protein approx. 274 aa in size. The truncated ORF1 in WeyAL and SterneR is comprised of 642 bp and may encode a protein approx. 214 aa in size.

-24-
The nucleotide sequence of the 822-bp ORF was used to search the GenBank and EMBL databases. The results revealed that the sequence shared a 56% identity with those of *Mycoplasma hyopneumoniae* ORF1 and ORF2 of a genetic element that Ferrell et al. (4) reported resembles a procaryotic insertion sequence, and *Mycoplasma hyorhinis* GDL-1 repeat region. The deduced amino acid sequence of the 822-bp ORF was then used to search the PIR-Protein and Swiss-Prot databases. The results showed that the deduced peptide shares homology with peptide sequences of probable transposases of *E. coli* IS150 (an IS3-related element) and IS150-related elements, e.g. *Streptococcus agalactiae* IS861. In addition, the translated product of the 822-bp ORF also exhibited homology to IS3 and other IS3-related transposases. The translated product of the 642-bp ORF also exhibited homology to IS150 and IS3; however, the product exhibited some differences at the carboxy terminus suggesting that the truncated ORF1 may encode a truncated transposase. Preliminary results from a Bestfit analysis of the 274-aa translated product showed that it exhibited a 42% identity and 60% similarity with IS150 ORFB translated product (thought to be a transposase) and a 31% identity and 52% similarity with the IS3 probable transposase.

A GenBank search of the nucleotide sequence of ORF2 (234 bp) and a SwissProt search of the putative amino acid sequence of ORF2 (78 aa) did not reveal any sequences or proteins of significance. Since ORF2 is immediately upstream of ORF1 and shifted by one base, then the two ORFs may encode a transframe protein composed of the product of ORF2 fused to that of ORF1. This phenomenon, known as translational frameshifting, is used by bacterial insertion sequences, e.g. IS1, IS150, and IS911, as a method of controlling transposition (3). Since the putative transposase encoded by ORF1 in WeyAR shares homology with IS150, then transposition of the putative IS element (WeyAR) of pXO1 may also be controlled by translational frameshifting. Further analysis would be necessary to determine whether ORF1 and ORF2 encode functional genes or encode a transframe protein.

**Distribution of Inverted repeats.** DNA-DNA hybridization of genomic DNA from *B. anthracis* with the 1.0-kb EcoRI-HindIII subcloned fragment of pJMH24 (WeyAR inverted repeat, subcloned from the 2.4-kb EcoRI fragment of pXO1 from Weybridge A UM23) was used to determine whether the inverted repeats can be detected in the chromosome and pXO2. Total genomic DNA was isolated from *B. anthracis* Weybridge A UM23 (pXO1+, pXO2), Weybridge A UM23-2 (pXO1+, pXO2), and Pasteur 4229 UM12 (pXO1+ , pXO2*). The 1.0-kb EcoRI-HindIII insert of pJMH24 was chosen as the DNA probe because it contains only DNA of the WeyAR inverted repeat with no extraneous DNA of pXO1. The results of the DNA-DNA hybridizations showed that the inverted repeat of WeyAR hybridized only to pXO1 and not to the chromosome or pXO2 (data not shown). Thus, these inverted repeats appear to be located only on pXO1. Although a putative transposase gene is present within the inverted repeats, the elements do not appear to transpose to other regions of the genome.

**Lack of correlation of observed phenotypes with orientation of the Inverted segment.** As discussed in the Midterm Report (22), differences between Steme and Weybridge A UM23 in the pXO1-
associated phenotypes, i.e., extent and rate of sporulation, ability to grow on minimal medium, and sensitivity to bacteriophage CP-51, did not correlate with the orientation (α or β) of the toxin-encoding region of pXO1. The amounts of PA, LF, and EF produced by B. anthracis Weybridge UM44-1, Weybridge A UM23, and Sterne in the presence or absence of bicarbonate were determined. The results, as shown in Table 9, varied between experiments; however, no significant differences in the amounts of PA, LF, or EF produced by these strains were apparent. Thus, we have been unable to demonstrate any phenotypic effects of the two orientations of the inverted segment.

III. Physical and genetic analysis of the B. anthracis capsule plasmid pXO2

Until recently B. anthracis strains harboring pXO2 could be divided into three groups with respect to capsule phenotype; (i) strains that produce capsule only when grown on media containing bicarbonate and incubated in a CO₂-rich atmosphere (Cap⁺, wild-type phenotype); (ii) mutants that produce capsule when grown in air in the absence of bicarbonate (Cap⁺ phenotype); and (iii) mutants that are noncapsulated under all growth conditions yet retain pXO2 (Cap⁻ phenotype). Utilization of the temperature-sensitive transposition selection vector pTV1 has allowed the isolation of a collection of pXO2::Tn917 derivatives. In addition to the mutant phenotypes described above, insertion mutants exhibit the following phenotypes: (i) Mutants that produce greater amounts of capsular material than does wild type in the presence of bicarbonate and CO₂; (ii) Mutants that are CO₂-independent for capsule synthesis and whose growth is inhibited by bicarbonate; (iii) Mutants that are Cap⁺ when grown in air, and whose growth is inhibited by CO₂; (iv) Mutants that require CO₂ for growth and are Cap⁺ in the presence of CO₂ and bicarbonate.

Although pXO2 has been demonstrated to be involved in capsule synthesis by B. anthracis (5, 28) and although some, if not all, of the structural genes have been cloned (12), little is known regarding possible regulatory genes which may be present on the plasmid. However, Vietri, et al. (29) recently reported the identification of a regulatory gene involved in capsule synthesis. The phenotypes of some of our insertion mutants suggest that Tn917 may be inserted in sequences involved in bicarbonate regulation of capsule synthesis.

Efforts in my laboratory have been concentrated on characterization of insertion mutants of pXO2. Restriction analysis with different enzymes has been conducted to narrow the location of the putative regulatory regions and they have revealed four regions that may contain sequences responsible for regulation of capsule synthesis. The work reported in the Midterm Report (22) is summarized below and followed by details of more recent results. For reference, a map of pXO2 is shown in Fig. 15.

Restriction analyses of the Tn917-tagged pXO2 derivatives from B. anthracis 4229 UM12. To locate the insertions in the pXO2::Tn917 derivatives restriction analyses with several restriction endonucleases were performed. The results showed that Tn917 inserted into a number of different sites in
pXO2. The locations of Tn917 were confirmed in all cases by DNA-DNA hybridizations using digoxigenin-labelled Tn917 as a probe. Results obtained from EcoR1 digestions, HindIII digestions, and CiaI digestions, which are detailed in tabular form in the Midterm Report (22), made it possible to locate more precisely the Tn917 insertions on the pXO2 restriction map reported by Robertson et al. (15). Based on this map as a reference, in nine of eleven mutants in which the capsule phenotype was altered, Tn917 appeared to have inserted into regions of pXO2 which are external to the cap structural genes. Specifically, in tp21, tp24, tp49, tp58, and tp60 a 6.3-kb EcoRI fragment and in tp18 and tp20 a 2.8-kb HindIII appeared to have regions involved in regulation of capsule synthesis. In the remaining two insertion mutants that had an altered capsule phenotype, i.e., tp22 and tp59, the transposon was located in a 1.5-kb and a 1.3-kb HindIII fragment, respectively. These two fragments are widely separated on the pXO2 map. The 6.3-kb EcoRI fragment has been shown to be nested within the 13-kb HindIII fragment and to be part of the 10.5-kb CiaI fragment, narrowing the location of the putative regulatory region.

Analysis of Insertion mutants that appear to be polypeptide overproducers. Insertion mutants tp49, tp50, and tp60 appeared to be polypeptide overproducers. The stringy properties of their colonies, the confluent growth they form on agar plates, and the loss of capsular material in a short period of time resemble polypeptide production by B. licheniformis. Tn917 has been shown by DNA-DNA hybridization experiments to be located in the chromosome of tp50 and in the capsule plasmid of tp49 and tp60. The phenotype of tp60 is different from that of tp49 and tp50 in that tp60 is CO2-independent for synthesis of capsular material. However, it overproduces capsular material only when it is grown in the presence of CO2. Restriction analysis of plasmid DNA from strains tp49 and tp60 show the same restriction pattern with insertion of Tn917 within the same fragment. To determine whether the orientation of Tn917 might account for the difference in these phenotypes, the orientation of Tn917 was determined by probing the HindIII-digested plasmids with the Aval arms of Tn917. The results showed that Tn917 is in the same orientation in pXO2 from both of these mutants.

Colonies of the mutants that are overproducers of glutamyl polypeptide are extremely mucoid and they spread over the agar surface much more than do colonies of the encapsulated wild-type. As noted above, the capsular material produced by the mutants appears to "dry up" after a rather short time of incubation. It appeared to us that the material was probably being degraded. This is characteristic of B. licheniformis strains which produce glutamyl polypeptide and which also produce a peptidase that hydrolyzes the peptide to free glutamic acid. An analogous enzyme has not been shown to be produced by B. anthracis. It should be pointed out, however, that recently Uchida, et al. (27) reported the occurrence of an enzyme produced by B. anthracis which degrades capsular poly-D-glutamic acid to smaller fragments. Unlike the enzyme from B. licheniformis the B. anthracis enzyme apparently did not degrade the peptide to free glutamic acid.

Results of our further experiments on the phenomenon reported above, which appeared to be complete degradation of capsular material by the over-producing mutants, have suggested another
possibility. We observed that when cells were grown on top of a dialysis membrane spread over the agar surface, the capsular material was still produced in large quantities but it did not "dry up" or disappear in the way that it appeared to when cells were grown directly on the agar surface. It now seems to us that in the overproducing mutants the capsular material is not "contained" in the same way that it is in wild-type cells, and it is therefore free to diffuse into the agar medium. However, when a dialysis membrane separates the cells from the agar surface, the material cannot go through the membrane and thus persists on the surface. These observations and interpretations suggest that the capsule of wild-type *B. anthracis* contains more than glutamyl polypeptide.

Quantitative determination of glutamyl polypeptide produced by overproducing mutants. To conduct quantitative determinations on the composition and amount of capsular material produced by the over-producing mutants described above, it was desirable to have a synthetic medium that would support capsule formation and polypeptide synthesis to the extent that many natural media do. Strain 4229 does not grow on minimal XO medium and it grows poorly on minimal IB, which is a suitable medium for growth of some strains. However, this strain grows well and produces capsular material on minimal IIIB (see Materials and Methods).

Dialysis membranes were placed on minimal IIIB-NaHCO₃ agar plates and three loopfuls of cells grown on LPACO₃ medium (for wild-type strain) and LPACO₃ containing erythromycin and lincomycin (for mutants) were spread on each of three plates. One set of three plates was incubated at 37°C in 20% CO₂ for 24 hours and another set was incubated under the same conditions for 48 hours. After incubation the membranes from three plates were removed from the agar surface with forceps, placed in a beaker containing 35 ml of distilled water, and autoclaved for 30 minutes at 121°C to extract the peptide. After autoclaving, the membranes were discarded and cells were removed by centrifugation. The supernatant samples were analyzed for glutamyl polypeptide by determining free glutamic acid (by paper chromatography) before and after acid hydrolysis (25, 10). Results from these experiments showed that the overproducing mutants, tp49, tp50, and tp60, produced approximately 1.7 times as much glutamyl polypeptide as did the parental wild-type strain (22).

Determination of the configuration of glutamic acid in glutamyl polypeptide produced by *B. anthracis* 4229 UM12 and insertion mutants tp49, tp50, and tp60. As pointed out above the appearance of colonies of the insertion mutants growing on media conducive to polypeptide production resembles that of *B. licheniformis* more than that of *B. anthracis*. Therefore, it was of interest to test whether the configuration of the glutamic acid in the capsular material of these mutants resembled that of glutamyl polypeptide produced by *B. licheniformis*. The latter organism produces an L-glutamyl polypeptide and a D-glutamyl polypeptide and the proportions of the two will vary depending on the Mn⁺⁺ concentration in the growth medium (10). Peptide was extracted from 4229 UM12 and the three insertion mutants by autoclaving encapsulated cells in aqueous suspension and isolated by precipitation with four volumes of ethanol. The precipitated peptide was dissolved in water and dialyzed against distilled water at 4°C. The
dialyzed samples were stirred for 30 min with Norit A (10 mg/ml), then centrifuged twice at 12,000 rpm for 20 min and filtered through Millipore DA filters to remove the Norit. The peptide was precipitated by adding saturated CuSO₄ solution until a precipitate no longer formed. Samples were centrifuged at 12,000 rpm for 20 min and the supernatant solutions were discarded. Pellets were dissolved in 1 N citric acid and the solutions were dialyzed against water at 4°C for 24 h. These solutions were centrifuged at 12,000 rpm for 20 min to remove any insoluble material and then lyophilized. The lyophilized samples were dried in vacuo overnight at 50°C. The peptide was suspended in sterile distilled water to a concentration of 1 mg/ml. Following acid hydrolysis samples were analyzed by paper chromatography for total glutamic acid. Paper chromatography showed that no amino acids other than glutamic acid were present after acid hydrolysis. L-Glutamic acid was determined by a method employing L-glutamic acid oxidase (United States Biochemical L-glutamic acid assay kit). D-glutamic acid was estimated by subtracting the amount of L-isomer from the total glutamic acid. Results (Table 10) from three different experiments show that the polypeptide from wild-type and mutant strains contained more than 98% D-glutamic acid. Thus, our conclusion is that the polypeptide produced by the insertion mutants does not differ from that produced by the parent strain with respect to the configuration of the glutamic acid.

Transduction of the chromosomal insertion mutation from B. anthracis 4229 UM12 tp50 to wild-type strains. Insertion mutant tp50, which is a polypeptide overproducer, has been shown to contain Tn917 within the chromosome. The mutation was transferred to B. anthracis 4229 UM12 and B. anthracis 6602 by CP-51-mediated transduction. Bacteriophage CP-51 was propagated on tp50 (CapC++, MLS') and tp50C1 (Cap, MLS', cured of pXO2). Recipient strains were streptomycin resistant and contained the capsule plasmid pXO2. Transductants were screened on LPA agar containing inhibitory concentrations of erythromycin, lincomycin and streptomycin. In all cases transductants showed overproduction of capsular material, providing more evidence that polypeptide overproduction by mutant tp50 is related to the chromosomal insertion of Tn917. DNA-DNA hybridization tests showed that transductants did not have Tn917 in pXO2.

More evidence that overproduction of the capsular material by mutant tp50 is related to the chromosomal insertion of Tn917 comes from experiments in which pXO2 from tp50 was transferred to strains cured of pXO2 by CP-51-mediated transduction. Bacteriophage CP-51 propagated on tp50 (CapC++, MLS') was used to transduce pXO2 into B. anthracis 4229 UM12C1 (cured of pXO2). Transductants were screened on LPACO₃ agar without any antibiotic selection. Bacteriophage CP-54, which lyses noncapsulated cells but does not adsorb to capsulated cells, was used to select CapC+ transductants. All pXO2+ transductants were MLS sensitive and they all exhibited the capsule phenotype of wild-type pXO2-containing strains, i.e., they were not polypeptide overproducers. This is further evidence that the chromosomal insertion in tp50 is responsible for polypeptide overproduction in that transposant.
Analysis of pXO2::Tn917 from mutant tp24-17, a deletion derivative. Mutant tp24-17 has a deleted version of pXO2 which is approximately only 10.5 kb in size including the transposon. Tp24-17 makes smooth, but not mucoid, colonies when grown in the presence of bicarbonate and CO₂. However, the amount of capsular material produced (if the smooth phenotype is indeed a reflection of synthesis of capsular material) is much less than that observed for wild-type pXO2-containing strains. Evidence that this mutant synthesizes some component of the capsule comes from experiments with bacteriophage CP-54 which can not adsorb to encapsulated cells, allowing selection of encapsulated cells. Smooth colonies of tp24-17 appear after two days of incubation on plates spread with CP-54. Results from DNA-DNA hybridization experiments show that the mutant plasmid in tp24 does not contain any of the cap structural genes identified by Makino, et al. (12, 13). However, colonies of tp24-17 are more smooth than colonies of strain TE704 which is the strain containing the cloned cap structural genes in plasmid pUBCAP1. These results, along with results shown below, suggest that this plasmid may contain a structural gene encoding an additional component of the capsule. The glutamyl polypeptide produced by B. anthracis is contained around the cell as a capsule but in B. licheniformis the glutamyl polypeptide is liberated into the growth medium. This difference suggests that there is more to the capsule of B. anthracis than just glutamyl polypeptide.

Plasmid DNA from tp24-17 gives two new fragments upon digestion with EcoRI, a 7.8 kb fragment and a 2.7 kb fragment. These fragments were isolated by electroelution, labeled with digoxigenin-labeled dUTP, and used as probes in DNA-DNA hybridization experiments to (i) locate their origin on pXO2 from B. anthracis 4229 UM12, and (ii) detect any homology with pXO2 from B. anthracis 6602, plasmid DNA from strain TE702, and the cloned cap structural genes in pUBCAP1.

In summary, the 7.8-kb EcoRI fragment hybridized to the following fragments of pXO2 and pTE702 from wild-type strains; (i) 6.3-kb and 4.2-kb EcoRI fragments, (ii) 13-kb HindIII fragment, (iii) 8.2-kb XbaI fragment. Similarly the 2.7-kb EcoRI fragment hybridized to the following fragments in pXO2 and pTE702 from wild-type strains; (i) 2.7-kb EcoRI fragment, (ii) 13-kb HindIII fragment, (iii) 8.5-kb XbaI fragment. No homology was found with the cap structural genes identified by Makino, et al. (12, 13).

Bacteriophage CP-51 was propagated on the insertion mutant tp24-17 and the lysate was used to transduce the deleted version of pXO2 into B. anthracis 4229 UM12C1 (cured of pXO2) and B. anthracis Davis TE704 which contains pUBCAP1 (carries the cloned cap genes, but produces rough colonies that are not resistant to CP-54). Transductants were selected on LPACO₃ agar containing inhibitory concentrations of erythromycin and lincomycin (for 4229 UM12C1) or these two antibiotics plus kanamycin (for TE704), and transduction plates were spread with phage CP-54 to select for Cap⁺ and/or smooth cells. No Cap⁺ transductants were found but several smooth (not mucoid) colonies were isolated and analyzed for their plasmid content. All of them were shown to harbor a plasmid which migrated at the same rate as the plasmid from the donor strain. In addition smooth transductants of TE704 carried a second plasmid, as expected, which migrated at the same rate as pUBCAP1. The smooth (not mucoid)
phenotype of the transductants derived from 4229 UM12C1 suggests strongly that the smooth phenotype is conferred by the small deletion derivative of pXO2. (No spontaneous smooth cells were found in control experiments in which 4229 UM12C1 or TE704 were plated with CP-54 in the absence of transducing phage). The smooth (not mucoid) transductants of TE704 suggest that pUBCAP1 and the pXO2 deletion derivative carried by tp24-17, and which confers the smooth phenotype, do not complement each other to produce fully encapsulated cells.

Transduction of pUBCAP1 from B. anthracis Davis TE704 to B. anthracis 4229 UM12C1 and insertion mutants 4229 UM12 tp6 and tp38. Insertion mutants tp6 and tp38 carry large deletions of about 20 kb and 50 kb, respectively. Each of the deletions includes the cap region, rendering the strains Cap-. However, each of the plasmids retains three of the four regions that are believed to be involved in regulation of capsule synthesis. Therefore, it was of interest to see whether pUBCAP1, which carries the cloned cap genes (12), and either of the deleted derivatives could complement each other to produce encapsulated cells.

Phage CP-51 was propagated on strain TE704 and the lysate was used to transfer pUBCAP1 to B. anthracis 4229 UM12C1 (cured of pXO2) and insertion mutants tp6, tp38, and tp24-17. Since pUBCAP1 carries the gene for kanamycin resistance, transductants of 4229 UM12C1 were selected on LPACO3 agar containing inhibitory concentrations of kanamycin and transductants of the three transposants were selected on LPACO3 agar containing inhibitory concentrations of erythromycin, lincomycin and kanamycin.

Several kanamycin-resistant transductants of 4229 UM12C1 were isolated. Plasmid profiles showed that they contained one plasmid that migrated to the same position as pUBCAP1 from the donor strain. Their phenotype was Cap+. Thus, the cloned cap genes carried by pUBCAP1 did not function in strain 4229 UM12C1 to produce encapsulated cells. (It should be recalled that strain TE704 which was obtained from I. Uchida and which carries pUBCAP1 is not encapsulated, presumably because regulatory genes are missing).

Several Kan' MLS' transductants of tp6 and tp38 were isolated and cells were analyzed for plasmid content. All transductants were shown to harbor two plasmids, one which migrated to the same position as pUBCAP1 and another which migrated the same as the plasmid from the respective recipient strain. Colonies of all such transductants showed a rough phenotype and could not be selected with bacteriophage CP-54. Thus, apparently complementation to produce encapsulated cells did not occur.

Attempts to clone the 2.8-kb HindIII and the 10.5-kb CiaI fragments into an E. coli host. Based on phenotypes of insertion mutants it seems that at least two to four regions of pXO2 may be involved in regulation of capsule synthesis. These include the 2.8-kb HindIII fragment and the 10.5-kb CiaI fragment. We made a few attempts to clone the putative regulatory genes into E. coli without any success. However, Ana Guaracao-Ayala, who was doing the work on characterization of pXO2 finished the requirements for the Ph.D. degree and returned to Colombia. Since I was approaching retirement from the university it was not feasible for me to accept another graduate student. Although I had hoped that Jan Homung might be
able to continue the cloning experiments, her work on characterizing the inversion in pXO1 consumed all of her time. Therefore, this part of the project was not completed.

IV. Investigation of phage TP-21 whose prophage is a plasmid

We have shown previously that the 46-kb plasmid of *Bacillus thuringiensis* subsp. *kurstaki* strain HD-1 is the prophage of a phage which we have named TP-21 (17, 21). This appears to be the first phage with a plasmid prophage described for the genus *Bacillus*. We have shown that TP-21 is a generalized transducing phage. It is likely that some of the transfer of genetic material attributed by other workers to conjugation-like processes in this strain is the result of TP-21-mediated transduction. TP-21 plaque-forming particles contain greater than 48 kilobase pairs of DNA which appears to be circularly permuted and terminally redundant. We isolated TP-21 lysogens which have the 5.2-kb MLS resistance transposon Tn917 inserted in the prophage. Although insertion of Tn917 rendered some isolates defective, several isolates carrying this element produced viable phage which conferred erythromycin resistance upon lysogenized hosts. Results of tests with TP-21::Tn917 demonstrated a broad host range among *B. anthracis*, *B. cereus* and *B. thuringiensis* strains.

TP-21 lysogens were very stable during growth at high temperatures. A mutant of TP-21, TP-21c7, was isolated following nitrosoguanidine mutagenesis of a *B. anthracis* lysogen; this derivative appeared to be temperature sensitive for replication. *B. cereus* lysogens of TP-21c7 grown at 30°C stably maintained the plasmid prophage. At 42°C strains apparently cured of TP-21c7 could be isolated from broth cultures grown from lysogens. A derivative of TP-21c7 was isolated which has Tn917 inserted. Lysogens of the transposon-tagged derivative, like those of the parental mutant phage, were stable at 30°C but apparently could be cured of the prophage at 42°C.

For many reasons TP-21c7::Tn917 seemed as if it should serve as an ideal transposition selection vector for *B. anthracis*, *B. cereus*, and *B. thuringiensis*. However, several experiments in which it was tested as a mutagenic vehicle for *B. cereus* and *B. anthracis* were unsuccessful. The reasons for this were not clear at first. However, results of experiments carried out under this contract have shown that the temperature-sensitive mutant of TP-21 which is tagged with Tn917 mutates to defective forms during the curing procedure at 42°C in the presence of erythromycin and lincomycin. Thus, colonies of *B. cereus* or *B. anthracis* that appeared to be transposants, i.e., ones that retained MLS resistance and seemed to be cured of TP-21 because they produced no lysis when planted in indicator lawns, were not transposants. Instead they harbored defective mutants of TP-21 which retained Tn917. Electrophoretic gels of plasmid extracts of presumed transposants revealed defective prophage plasmids of various sizes. Because the presence of erythromycin and lincomycin during the curing procedure apparently selected for defective phage mutants that were not temperature sensitive for replication, we carried out some experiments in which the curing procedure was done without selection for antibiotic resistance. However, these
experiments were unsuccessful. The frequency of MLSr colonies that were cured of TP-21 was too low for this procedure to be useful for transposon mutagenesis. Because of these findings we discontinued work on this problem early in the contract period, electing to put our full effort into studying the biology of the B. anthracis plasmids pXO1 and pXO2.

CONCLUSIONS

The significance of the inversion of the toxin encoding region of pXO1 carried by the Sterne (USAMRIID) strain is not clear. Thus far, no phenotypic changes can be associated with the inversion. If the segment is actively invertible, it seems likely that the frequency of inversion is quite low. However, because there is no known phenotype attributable to either orientation of the segment, there is no obvious way to select cells in which the inversion has occurred.

The discovery of the positive regulatory gene for toxin synthesis, atxA, made possible by the utilization of transposon mutagenesis, is probably the single most important accomplishment resulting from our work on pXO1 during this contract period. Another potentially important accomplishment is the demonstration of what appears to be insertional inactivation of a negative regulatory gene involved in toxin synthesis. However, our preliminary attempts to clone the putative negative regulatory gene were unsuccessful. Unfortunately time did not permit further investigation of this intriguing problem. If I were to continue working on B. anthracis, this problem would have high priority.

With respect to the capsule plasmid, pXO2, several interesting problems remain. Although the group at USAMRIID has recently reported the discovery of a regulatory gene involved in capsule synthesis, our studies strongly suggest that additional regulatory genes for capsule synthesis are located on pXO2. One of our most interesting findings is that insertion of transposon Tn917 into the chromosome at an undetermined site resulted in overproduction of capsular material. The nature of this enhancement of capsule synthesis is unknown and should be investigated further. Another problem that I would enjoy investigating further is the possibility that other gene(s) in addition to those responsible for synthesis of polyglutamic acid may be involved in capsule synthesis. This supposes that polyglutamic acid is not the only constituent of the B. anthracis capsule and that one or more additional components function to "contain" the polyglutamic acid around the cells as a capsule. This final report includes some evidence for this.

-33-
Table 1. Bacterial strains and plasmids used in this report

<table>
<thead>
<tr>
<th>Strain or plasmid</th>
<th>Relevant Characteristics</th>
<th>Plasmids</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>B. anthracis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anvax</td>
<td>Tox⁺</td>
<td>pXO1</td>
<td>Jensen-Salsberg Laboratories</td>
</tr>
<tr>
<td>PM36-R1</td>
<td>Tox⁺</td>
<td>pXO1</td>
<td>C. B. Thome</td>
</tr>
<tr>
<td>Sterne</td>
<td>Tox⁺</td>
<td>pXO1</td>
<td>USAMRIID</td>
</tr>
<tr>
<td>Vollum V770</td>
<td>Tox⁺</td>
<td>pXO1</td>
<td>C. B. Thome</td>
</tr>
<tr>
<td>Weybridge</td>
<td>Tox⁺</td>
<td>pXO1</td>
<td>Microbiological Research Establishment, Porton, England</td>
</tr>
<tr>
<td>UM44-1</td>
<td>Ind⁺, Tox⁺</td>
<td>pXO1</td>
<td>C. B. Thome</td>
</tr>
<tr>
<td>Weybridge A</td>
<td>Tox⁺</td>
<td>pXO1.1</td>
<td>C. B. Thome</td>
</tr>
<tr>
<td>A UM23</td>
<td>Ura⁺, Tox⁺</td>
<td>pXO1.1</td>
<td>C. B. Thome</td>
</tr>
<tr>
<td>A UM23 tp1A</td>
<td>Ura⁺, PA⁺, LF⁺, EF⁺, MLS⁻</td>
<td>pXO1.1::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>A UM23 tp2A</td>
<td>Ura⁺, PA⁺, LF⁺, EF⁺, MLS⁻</td>
<td>pXO1.1::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>A UM23 tp21</td>
<td>Ura⁺, MLS⁻, PA⁺, LF⁺, EF⁺, Δpag</td>
<td>pXO1.1::Tn917 deletion derivative (Δ15 kb)</td>
<td>This study</td>
</tr>
<tr>
<td>A UM23 tp29</td>
<td>Ura⁺, MLS⁻, PA⁺, LF⁺, EF⁺, abxA::Tn917</td>
<td>pXO1.1::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>A UM23 tp29 (pHY300PLK)</td>
<td>Ura⁺, MLS⁻, Tc⁺, PA⁺, LF⁺, EF⁺, abxA::Tn917</td>
<td>pXO1.1::Tn917, pHY300PLK</td>
<td>Uchida et al. (26)</td>
</tr>
<tr>
<td>A UM23 tp29 (pLU68)</td>
<td>Ura⁺, MLS⁻, Tc⁺, PA⁺, LF⁺, EF⁺, abxA::Tn917</td>
<td>pXO1.1::Tn917, pLU68</td>
<td>Uchida et al. (26)</td>
</tr>
<tr>
<td>A UM23 tp32</td>
<td>Ura⁺, MLS⁻, PA⁺, LF⁺, EF⁺, abxA::Tn917</td>
<td>pXO1.1::Tn917</td>
<td>This study</td>
</tr>
</tbody>
</table>

Continued next page
<table>
<thead>
<tr>
<th>Strain or plasmid&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Relevant Characteristics&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Plasmids</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>A UM23 tp32 (pHY300PLK)</td>
<td>Superior, MLS&lt;sup&gt;+&lt;/sup&gt;, Tc&lt;sup&gt;+&lt;/sup&gt;, PA&lt;sup&gt;+&lt;/sup&gt;, LF&lt;sup&gt;+&lt;/sup&gt;, EF&lt;sup&gt;+&lt;/sup&gt;, abxA&lt;sup&gt;+&lt;/sup&gt;, Pag&lt;sup&gt;+&lt;/sup&gt;, cya&lt;sup&gt;-&lt;/sup&gt;, abxA&lt;sup&gt;-&lt;/sup&gt;</td>
<td>pXO1.1::Tn917, pHY300PLK</td>
<td>Uchida et al. (26)</td>
</tr>
<tr>
<td>A UM23 tp32 (plU68)</td>
<td>Superior, MLS&lt;sup&gt;+&lt;/sup&gt;, Tc&lt;sup&gt;+&lt;/sup&gt;, PA&lt;sup&gt;+&lt;/sup&gt;, LF&lt;sup&gt;+&lt;/sup&gt;, EF&lt;sup&gt;+&lt;/sup&gt;, abxA&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO1.1::Tn917, plU68</td>
<td>Uchida et al. (26)</td>
</tr>
<tr>
<td>A UM23 tp36</td>
<td>Superior, PA&lt;sup&gt;+&lt;/sup&gt;, LF&lt;sup&gt;+&lt;/sup&gt;, EF&lt;sup&gt;+&lt;/sup&gt;, MLS&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO1.1::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>A UM23 tp39</td>
<td>Superior, MLS&lt;sup&gt;+&lt;/sup&gt;, Tc&lt;sup&gt;+&lt;/sup&gt;, PA&lt;sup&gt;+&lt;/sup&gt;, LF&lt;sup&gt;+&lt;/sup&gt;, EF&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO1.1::Tn917 deletion derivative (Δ27 kb)</td>
<td>This study</td>
</tr>
<tr>
<td>A UM23 tp39 etf3 and etf5</td>
<td>Superior, MLS&lt;sup&gt;+&lt;/sup&gt;, Tc&lt;sup&gt;+&lt;/sup&gt;, PA&lt;sup&gt;+&lt;/sup&gt;, LF&lt;sup&gt;+&lt;/sup&gt;, EF&lt;sup&gt;+&lt;/sup&gt;, abxA&lt;sup&gt;+&lt;/sup&gt;, Pag&lt;sup&gt;-&lt;/sup&gt;, cya&lt;sup&gt;-&lt;/sup&gt;, abxA&lt;sup&gt;-&lt;/sup&gt;</td>
<td>pXO1.1::Tn917 deletion derivative (Δ27 kb), plU51</td>
<td>This study</td>
</tr>
<tr>
<td>A UM23 tp49</td>
<td>Superior, MLS&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO1.1::Tn917 deletion derivative (Δ150 kb)</td>
<td>This study</td>
</tr>
<tr>
<td>A UM23 tp62</td>
<td>Superior, MLS&lt;sup&gt;+&lt;/sup&gt;, PA&lt;sup&gt;+&lt;/sup&gt;+, LF&lt;sup&gt;+&lt;/sup&gt;+, EF&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO1.1::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>A UM23 tp62 (pHY300PLK)</td>
<td>Superior, MLS&lt;sup&gt;+&lt;/sup&gt;, Tc&lt;sup&gt;+&lt;/sup&gt;, PA&lt;sup&gt;+&lt;/sup&gt;+, LF&lt;sup&gt;+&lt;/sup&gt;+, EF&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO1.1::Tn917, pHY300PLK</td>
<td>Uchida et al. (26)</td>
</tr>
<tr>
<td>A UM23 tp62 (plU68)</td>
<td>Superior, MLS&lt;sup&gt;+&lt;/sup&gt;, Tc&lt;sup&gt;+&lt;/sup&gt;, PA&lt;sup&gt;+&lt;/sup&gt;+, LF&lt;sup&gt;+&lt;/sup&gt;+, EF&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO1.1::Tn917, plU68</td>
<td>Uchida et al. (26)</td>
</tr>
<tr>
<td>A UM23 tp71</td>
<td>Superior, MLS&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO1.1::Tn917 deletion derivative (Δ142 kb)</td>
<td>This study</td>
</tr>
<tr>
<td>A UM23 tp72</td>
<td>Superior, MLS&lt;sup&gt;+&lt;/sup&gt;, PA&lt;sup&gt;+&lt;/sup&gt;+, LF&lt;sup&gt;+&lt;/sup&gt;+, EF&lt;sup&gt;+&lt;/sup&gt;, abxA&lt;sup&gt;+&lt;/sup&gt;, Pag&lt;sup&gt;+&lt;/sup&gt;, cya&lt;sup&gt;-&lt;/sup&gt;, abxA&lt;sup&gt;-&lt;/sup&gt;</td>
<td>pXO1.1::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>A UM23-1</td>
<td>Superior, Str&lt;sup&gt;+&lt;/sup&gt;, Tc&lt;sup&gt;+&lt;/sup&gt;, Tox&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO1.1</td>
<td>C. B. Thome</td>
</tr>
<tr>
<td>A UM23-1 (pHY300PLK)</td>
<td>Superior, Str&lt;sup&gt;+&lt;/sup&gt;, Tc&lt;sup&gt;+&lt;/sup&gt;, Tox&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO1.1, pHY300PLK</td>
<td>Uchida et al. (26)</td>
</tr>
<tr>
<td>A UM23-1 (plU68)</td>
<td>Superior, Str&lt;sup&gt;+&lt;/sup&gt;, Tc&lt;sup&gt;+&lt;/sup&gt;, Tox&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO1.1, plU68</td>
<td>Uchida et al. (26)</td>
</tr>
<tr>
<td>A UM23C1</td>
<td>Superior, Str&lt;sup&gt;+&lt;/sup&gt;, Tc&lt;sup&gt;+&lt;/sup&gt;, Tox&lt;sup&gt;-&lt;/sup&gt;</td>
<td>(pXO1.1)</td>
<td>C. B. Thome</td>
</tr>
<tr>
<td>A UM23C1-1</td>
<td>Superior, Str&lt;sup&gt;+&lt;/sup&gt;, Tc&lt;sup&gt;+&lt;/sup&gt;, Tox&lt;sup&gt;-&lt;/sup&gt;</td>
<td>(pXO1.1)</td>
<td>C. B. Thome</td>
</tr>
</tbody>
</table>

Continued next page
Table 1. Continued

<table>
<thead>
<tr>
<th>Strain or plasmid&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Relevant Characteristics&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Plasmids</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>A UM23C1-1 (pH71)</td>
<td>Ura&lt;sup&gt;+&lt;/sup&gt;, Str&lt;sup&gt;+&lt;/sup&gt;, Km&lt;sup&gt;+&lt;/sup&gt;, Tox&lt;sup&gt;-&lt;/sup&gt;</td>
<td>(pXO1.1)&lt;sup&gt;+&lt;/sup&gt;, pH71</td>
<td>Uchida et al. (26)</td>
</tr>
<tr>
<td>A UM23C1-1 (pH71, pH300PLK)</td>
<td>Ura&lt;sup&gt;+&lt;/sup&gt;, Str&lt;sup&gt;+&lt;/sup&gt;, Km&lt;sup&gt;+&lt;/sup&gt;, Tox&lt;sup&gt;-&lt;/sup&gt;</td>
<td>(pXO1.1)&lt;sup&gt;+&lt;/sup&gt;, pH71, pH300PLK</td>
<td>Uchida et al. (26)</td>
</tr>
<tr>
<td>A UM23C1-1 (pH71, pH68)</td>
<td>Ura&lt;sup&gt;+&lt;/sup&gt;, Str&lt;sup&gt;+&lt;/sup&gt;, Km&lt;sup&gt;+&lt;/sup&gt;, Tox&lt;sup&gt;-&lt;/sup&gt;</td>
<td>(pXO1.1)&lt;sup&gt;+&lt;/sup&gt;, pH71, pH68</td>
<td>Uchida et al. (26)</td>
</tr>
<tr>
<td>A UM23C1-2</td>
<td>Ura&lt;sup&gt;+&lt;/sup&gt;, Rif&lt;sup&gt;+&lt;/sup&gt;, Tox&lt;sup&gt;-&lt;/sup&gt;</td>
<td>(pXO1.1)&lt;sup&gt;+&lt;/sup&gt;</td>
<td>C. B. Thorne</td>
</tr>
<tr>
<td>B</td>
<td>Tox&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO1</td>
<td>C. B. Thorne</td>
</tr>
<tr>
<td>Davis</td>
<td>Cap&lt;sup&gt;c+&lt;/sup&gt;</td>
<td>pTE702</td>
<td>I. Uchida</td>
</tr>
<tr>
<td>TE702</td>
<td>Cap&lt;sup&gt;c+&lt;/sup&gt;</td>
<td>pUBCAP1</td>
<td>I. Uchida</td>
</tr>
<tr>
<td>Pasteur</td>
<td>Cap&lt;sup&gt;c+&lt;/sup&gt;</td>
<td>pXO2</td>
<td>USAMRIID</td>
</tr>
<tr>
<td>6602</td>
<td>Cap&lt;sup&gt;c+&lt;/sup&gt;</td>
<td>pXO2</td>
<td>USAMRIID</td>
</tr>
<tr>
<td>4229</td>
<td>Cap&lt;sup&gt;c+&lt;/sup&gt;</td>
<td>pXO2</td>
<td>C.B. Thorne</td>
</tr>
<tr>
<td>4229UM12</td>
<td>Cap&lt;sup&gt;c+&lt;/sup&gt;, NaI&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO2</td>
<td>C.B. Thorne</td>
</tr>
<tr>
<td>4229UM12 tp1</td>
<td>Cap&lt;sup&gt;c+&lt;/sup&gt;, NaI&lt;sup&gt;+&lt;/sup&gt;, MLS&lt;sup&gt;+&lt;/sup&gt;, Cm&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp3</td>
<td>Cap&lt;sup&gt;c+&lt;/sup&gt;, NaI&lt;sup&gt;+&lt;/sup&gt;, MLS&lt;sup&gt;+&lt;/sup&gt;, Cm&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp4</td>
<td>Cap&lt;sup&gt;c+&lt;/sup&gt;, NaI&lt;sup&gt;+&lt;/sup&gt;, MLS&lt;sup&gt;+&lt;/sup&gt;, Cm&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp6</td>
<td>Cap&lt;sup&gt;+&lt;/sup&gt;, NaI&lt;sup&gt;+&lt;/sup&gt;, MLS&lt;sup&gt;+&lt;/sup&gt;, Cm&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp7</td>
<td>Cap&lt;sup&gt;+&lt;/sup&gt;, NaI&lt;sup&gt;+&lt;/sup&gt;, MLS&lt;sup&gt;+&lt;/sup&gt;, Cm&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp10</td>
<td>Cap&lt;sup&gt;c+&lt;/sup&gt;, NaI&lt;sup&gt;+&lt;/sup&gt;, MLS&lt;sup&gt;+&lt;/sup&gt;, Cm&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp11</td>
<td>Cap&lt;sup&gt;c+&lt;/sup&gt;, NaI&lt;sup&gt;+&lt;/sup&gt;, MLS&lt;sup&gt;+&lt;/sup&gt;, Cm&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp17</td>
<td>Cap&lt;sup&gt;c+&lt;/sup&gt;, NaI&lt;sup&gt;+&lt;/sup&gt;, MLS&lt;sup&gt;+&lt;/sup&gt;, Cm&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp18</td>
<td>Cap&lt;sup&gt;+&lt;/sup&gt;, NaI&lt;sup&gt;+&lt;/sup&gt;, MLS&lt;sup&gt;+&lt;/sup&gt;, Cm&lt;sup&gt;+&lt;/sup&gt;</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
</tbody>
</table>

Continued next page
Table 1. Continued

<table>
<thead>
<tr>
<th>Strain or plasmid</th>
<th>Relevant Characteristics</th>
<th>Plasmids</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>4229UM12 tp20</td>
<td>Cap⁺, Nař, MLS⁺, Cm⁶</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp21</td>
<td>Cap⁺, Nař, MLS⁺, Cm⁶</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp22</td>
<td>Cap⁺, Nař, MLS⁺, Cm⁶</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp24</td>
<td>Cap⁺⁺, Nař, MLS⁺, Cm⁶</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp24-17</td>
<td>Cap⁺⁺⁺, Nař, MLS⁺, Cm⁶</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp30</td>
<td>Cap⁺⁺⁺, Nař, MLS⁺, Cm⁶</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp38</td>
<td>Cap⁺⁺⁺, Nař, MLS⁺, Cm⁶</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp40</td>
<td>Cap⁺⁺⁺, Nař, MLS⁺, Cm⁶</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp49</td>
<td>Cap⁺⁺⁺⁺, Nař, MLS⁺, Cm⁶</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp58</td>
<td>Cap⁺⁺⁺⁺, Nař, MLS⁺, Cm⁶</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp59</td>
<td>Cap⁺⁺⁺⁺, Nař, MLS⁺, Cm⁶</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
<tr>
<td>4229UM12 tp60</td>
<td>Cap⁺⁺⁺⁺, Nař, MLS⁺, Cm⁶</td>
<td>pXO2::Tn917</td>
<td>This study</td>
</tr>
</tbody>
</table>

Plasmids

<table>
<thead>
<tr>
<th>Plasmid</th>
<th>Description</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>pHY300PLK</td>
<td><em>E. coli-B. subtilis</em> shuttle vector, Ap⁺, Tc⁺</td>
<td>See Uchida et al. (25)</td>
</tr>
<tr>
<td>pLUs1</td>
<td>5.0-kb insert containing abxA, cloned into pHY300PLK</td>
<td>Uchida et al. (26)</td>
</tr>
<tr>
<td>pLUs68</td>
<td>2.0-kb insert containing only abxA ORF, cloned into pHY300PLK</td>
<td>Uchida et al. (26)</td>
</tr>
</tbody>
</table>

Continued next page
<table>
<thead>
<tr>
<th>Strain or plasmid&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Relevant Characteristics&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Plasmids</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>pLU71</td>
<td>6.0-kb BamHI fragment of pXO1 containing pfg in pAT187, Ap&lt;sup&gt;+&lt;/sup&gt;, Km&lt;sup&gt;+&lt;/sup&gt;</td>
<td></td>
<td>Uchida et al. (26)</td>
</tr>
<tr>
<td>pJMH4</td>
<td>WeyAR, 2.4-kb EcoRI fragment of pXO1.1 (Weybridge A UM23), cloned into pBluescriptIIKS&lt;sup&gt;+&lt;/sup&gt;</td>
<td></td>
<td>This study</td>
</tr>
<tr>
<td>pJMH5</td>
<td>S. perespereus, 3.1-kb EcoRI fragment of pXO1 (S. perespereus), cloned into pBluescriptIIKS&lt;sup&gt;+&lt;/sup&gt;</td>
<td></td>
<td>This study</td>
</tr>
<tr>
<td>pJMH9</td>
<td>WeyAR, 5.4-kb EcoRI fragment of pXO1.1 (Weybridge A UM23), cloned into pBluescriptIIKS&lt;sup&gt;+&lt;/sup&gt;</td>
<td></td>
<td>This study</td>
</tr>
<tr>
<td>pJMH10</td>
<td>S. perespereus, 4.8-kb EcoRI fragment of pXO1 (S. perespereus), cloned into pBluescriptIIKS&lt;sup&gt;+&lt;/sup&gt;</td>
<td></td>
<td>This study</td>
</tr>
<tr>
<td>pJMH12</td>
<td>WeyAR, 2.7-kb KpnI fragment from 5.4-kb EcoRI fragment of pXO1.1 (Weybridge A UM23), subcloned into pBluescriptIIKS&lt;sup&gt;+&lt;/sup&gt;</td>
<td></td>
<td>This study</td>
</tr>
<tr>
<td>pJMH16</td>
<td>S. perespereus, 1.9-kb KpnI fragment from 4.8-kb EcoRI fragment of pXO1 (S. perespereus), subcloned into pBluescriptIIKS&lt;sup&gt;+&lt;/sup&gt;</td>
<td></td>
<td>This study</td>
</tr>
<tr>
<td>pJMH20</td>
<td>S. perespereus, 1.7-kb HindIII fragment from 3.1-kb EcoRI fragment of pXO1 (S. perespereus), subcloned into pBluescriptIIKS&lt;sup&gt;+&lt;/sup&gt;</td>
<td></td>
<td>This study</td>
</tr>
</tbody>
</table>

Continued next page
<table>
<thead>
<tr>
<th>Strain or plasmid^a</th>
<th>Relevant Characteristics^b</th>
<th>Plasmids</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>pJMH24</td>
<td>WeyAR, 1.0-kb HindIII fragment from 2.4-kb EcoRI fragment of pXO1.1 (Weybridge A UM23), subcloned into pBluescriptIKS+</td>
<td>This study</td>
<td></td>
</tr>
<tr>
<td>pJMH28</td>
<td>9.3-kb PstI fragment of pXO1 (Weybridge A UM23), cloned into pBluescriptIKS+ (contains WeyAR)</td>
<td>This study</td>
<td></td>
</tr>
</tbody>
</table>

^a tp, insertion mutant; etf, transformant by electroporation.

^b Abbreviations: Ap\(^{f}\), plasmid-encoded ampicillin resistance; Cap\(^{c+}\), capsule synthesis in presence of CO\(_2\) and bicarbonate; Cap\(^{c+}\), capsule synthesis in air; Cap\(^{c-}\), inability to synthesize capsule; Cap\(^{c++}\), overproduction of capsular material in the presence of CO\(_2\) and bicarbonate; EF\(^{+}\), production of edema factor; EF\(^{++}\), production of edema factor in the presence or absence of added sodium bicarbonate; EF\(^{-}\), no edema factor detected; Ind\(^{+}\), indole; Km\(^{f}\), plasmid-encoded kanamycin resistance; Lac, lactose utilization; LF\(^{+}\), production of lethal factor; LF\(^{++}\), overproduction of lethal factor in the presence or absence of added sodium bicarbonate; LF\(^{-}\), no lethal factor detected; MLS\(^{f}\), Tn\(_{817}\)-encoded macrolide, lincosamide, and streptogramin B resistance; Nal, nalidixic acid; PA\(^{+}\), production of protective antigen; PA\(^{++}\), overproduction of protective antigen in the presence or absence of added sodium bicarbonate; PA\(^{+/-}\), negligible quantities of protective antigen produced; PA\(^{-}\), no protective antigen detected; Rif\(^{+}\), rifampycin resistance; Str\(^{+}\), streptomycin resistance; Tc\(^{-}\), plasmid-encoded tetracycline resistance; Tox\(^{+}\), production of anthrax toxin; Tox\(^{-}\), no anthrax toxin detected; Ura, uracil; pag, PA structural gene; lef, LF structural gene; cya, EF structural gene; atxA, trans-activator of pag, lef, and cya.
Table 2. Yields of toxin components produced by *B. anthracis* Weybridge A UM23 and UM23 insertion mutants grown in the absence of added bicarbonate and horse serum\(^a\)

<table>
<thead>
<tr>
<th>Filtrate</th>
<th>CA-HEPES without bicarbonate and horse serum(^b)</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>UM23 (pXO1.1(^+))</td>
<td>PA, (\mu g/mg) dry wt.</td>
<td>LF, (\mu g/mg) dry wt.</td>
<td>EF, (\mu g/mg) dry wt.</td>
<td></td>
</tr>
<tr>
<td>UM23C1 (pXO1.1)</td>
<td>0</td>
<td>&lt;0.4</td>
<td>&lt;0.2</td>
<td></td>
</tr>
<tr>
<td>UM23 tp2A</td>
<td>1 ± 0.6</td>
<td>&lt;0.4</td>
<td>&lt;0.2</td>
<td></td>
</tr>
<tr>
<td>UM23 tp21(^c)</td>
<td>0</td>
<td>&lt;0.4</td>
<td>&lt;0.2</td>
<td></td>
</tr>
<tr>
<td>UM23 tp29</td>
<td>0</td>
<td>0</td>
<td>&lt;0.1</td>
<td></td>
</tr>
<tr>
<td>UM23 tp32</td>
<td>0</td>
<td>0</td>
<td>&lt;0.1</td>
<td></td>
</tr>
<tr>
<td>UM23 tp39(^c)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>UM23 tp62</td>
<td>40 ± 10</td>
<td>3 ± 0.3</td>
<td>1 ± 0.4</td>
<td></td>
</tr>
<tr>
<td>UM23 tp72</td>
<td>&lt;0.3</td>
<td>2 ± 1</td>
<td>≤0.4</td>
<td></td>
</tr>
</tbody>
</table>

* Cultures were grown in 100 ml of CA-HEPES (pH 7.5) broth in the absence of added sodium bicarbonate and horse serum in 250-ml screw-capped flasks at 37\(^\circ\)C with slow shaking (100 rpm). Uracil was added to a final concentration of 40 \(\mu g/ml\) to satisfy the auxotrophic requirement. Filtrates were collected from cultures grown for 14 h.

\(^b\) PA and LF concentrations were determined by radial immunodiffusion assays using goat antiserum to PA or rabbit antiserum to LF (provided by S. Leppla, NIDR, Bethesda, MD). EF concentrations were determined by adenylate cyclase assays. The values shown for the concentrations of PA, LF, and EF in the cultures filtrates are the averages of three experiments.

\(^c\) These insertion mutants contain deletions within pXO1.1::Tn917 derivatives.
Table 3. Origins of the altered BamHI-SalI fragments of pXO1.1::Tn917 deletion derivatives from UM23 tp21 and tp39

<table>
<thead>
<tr>
<th>Probe</th>
<th>Hybridizations to restriction fragments (kb) of pXO1.1 (Weybridge A UM23) generated by:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BamHI</td>
</tr>
<tr>
<td>36-kb BamHI-SalI fragment of pXO1.1::Tn917 (tp21)</td>
<td>34.8</td>
</tr>
<tr>
<td>8.5-kb BamHI-SalI fragment of pXO1.1::Tn917 (tp21)</td>
<td>13.9</td>
</tr>
<tr>
<td>33-kb BamHI-SalI fragment of pXO1.1::Tn917 (tp39)</td>
<td>34.8</td>
</tr>
<tr>
<td>5.5-kb BamHI-SalI fragment of pXO1.1::Tn917 (tp39)</td>
<td>7.4</td>
</tr>
</tbody>
</table>

<sup>a</sup> The BamHI-SalI fragments were isolated from agarose gels by electroelution and labelled with digoxigenin-labelled dUTP.

<sup>b</sup> ND, not done.
Table 4. Production of anthrax toxin components by *B. anthracis* strains complemented with the cloned atxA gene

<table>
<thead>
<tr>
<th>Strain</th>
<th>Plasmids</th>
<th>Toxin Components in Filtratesa (μg/ml)</th>
<th>PA</th>
<th>LF</th>
<th>EF</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>UM23</td>
<td>pXO1.1</td>
<td></td>
<td>0.5</td>
<td>18</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>UM23-1</td>
<td>pXO1.1</td>
<td></td>
<td>≤0.2</td>
<td>5.9</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>UM23-1</td>
<td>pXO1.1, pHY300PLK</td>
<td></td>
<td>&lt;0.1</td>
<td>5.1</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>UM23-1</td>
<td>pXO1.1, pLU68</td>
<td></td>
<td>0.2b</td>
<td>NGb</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>UM23 tp29</td>
<td>pXO1.1::Tn917</td>
<td></td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>UM23 tp29</td>
<td>pXO1.1::Tn917, pHY300PLK</td>
<td></td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>UM23 tp29</td>
<td>pXO1.1::Tn917, pLU68</td>
<td></td>
<td>7.0</td>
<td>6.5</td>
<td>0.7</td>
</tr>
<tr>
<td>UM23 tp32</td>
<td>pXO1.1::Tn917</td>
<td></td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>UM23 tp32</td>
<td>pXO1.1::Tn917, pHY300PLK</td>
<td></td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>UM23 tp32</td>
<td>pXO1.1::Tn917, pLU68</td>
<td></td>
<td>1.6</td>
<td>3.0</td>
<td>0.3</td>
</tr>
<tr>
<td>UM23 tp62</td>
<td>pXO1.1::Tn917</td>
<td></td>
<td>16</td>
<td>30</td>
<td>1.0</td>
</tr>
<tr>
<td>UM23 tp62</td>
<td>pXO1.1::Tn917, pHY300PLK</td>
<td></td>
<td>4.6</td>
<td>22</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>UM23 tp62</td>
<td>pXO1.1::Tn917, pLU68</td>
<td></td>
<td>1.8b</td>
<td>4.0b</td>
<td>≤0.5</td>
</tr>
<tr>
<td>UM23C1-1</td>
<td>pLU71</td>
<td></td>
<td>&lt;0.2</td>
<td>&lt;0.2</td>
<td>&lt;0.2</td>
</tr>
<tr>
<td>UM23C1-1</td>
<td>pLU71, pHY300PLK</td>
<td></td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>UM23C1-1</td>
<td>pLU71, pLU68</td>
<td></td>
<td>≤0.4</td>
<td>2.2</td>
<td>&lt;0.1</td>
</tr>
</tbody>
</table>

a The concentrations of the toxin components in the filtrates obtained from cultures growth in CA-HEPES (pH 7.5) in the absence (-) or presence (+) of 0.72% sodium bicarbonate and 3% horse serum were determined by radial immunodiffusion (PA and LF) or adenylate cyclase (EF) assays. All strains carrying pHY300PLK or recombinant plasmids, pLU68 or pLU71, were grown in the presence of tetracycline, kanamycin, or both antibiotics.

b The cultures did not grow (NG) or they grew slowly.
<table>
<thead>
<tr>
<th>Filterate</th>
<th>UM23</th>
<th>UM23 C1</th>
<th>UM23 tps3</th>
<th>UM23 tps3 eff3</th>
<th>UM23 tps3 eff5</th>
</tr>
</thead>
<tbody>
<tr>
<td>PA&lt;sub&gt;4&lt;/sub&gt;</td>
<td>36</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>LF&lt;sub&gt;4&lt;/sub&gt;</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>EF&lt;sub&gt;4&lt;/sub&gt;</td>
<td>&lt;0.2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Cultures were grown in 100 ml of CA-HEPES (pH 7.5) broth in the presence or absence of 0.72% sodium bicarbonate and 3% horse serum in 250-ml screw-capped flasks at 37°C with slow shaking (100 rpm). Filtrates were collected from cultures grown for 13 h in broth supplemented with sodium bicarbonate and horse serum or for 14 h in broth without added bicarbonate and horse serum.

Same as Table 2 footnote. The values obtained for the concentrations of PA<sub>4</sub>, LF<sub>4</sub>, and EF<sub>4</sub> in the filtrates from cultures grown in the presence or absence of added bicarbonate and horse serum are the averages of two experiments.
Table 6. Restriction analysis of the 14.6-kb BamHI fragment of pXO1.1 (Weybridge A UM23)

Sizes of restriction fragments (kb) of the 14.6-kb BamHI fragment generated by:

<table>
<thead>
<tr>
<th>EcoRI</th>
<th>EcoRI and Clal</th>
<th>Clal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>ca. 10.5</td>
</tr>
<tr>
<td>5.4</td>
<td></td>
<td>4.2</td>
</tr>
<tr>
<td>4.2</td>
<td></td>
<td>4.0</td>
</tr>
<tr>
<td>3.2</td>
<td></td>
<td>2.8</td>
</tr>
<tr>
<td>2.2</td>
<td></td>
<td>1.5</td>
</tr>
<tr>
<td>1.3</td>
<td></td>
<td>1.3</td>
</tr>
<tr>
<td>0.9</td>
<td></td>
<td>0.9</td>
</tr>
</tbody>
</table>

Figure 2. Construction of EcoRI and Clal restriction maps of the 14.6-kb BamHI fragment of pXO1.1 (Weybridge A UM23). The BamHI fragment was digested with Clal, EcoRI, or double digested with both enzymes. The sizes of the fragments (kb) from each digestion are shown.
Table 7. EcoRI digestion of BamHI-SalI fragments of pXO1.1::Tn917 derivatives from *B. anthracis* Weybridge A UM23 tp2A, tp36, and tp62

<table>
<thead>
<tr>
<th>Sizes of EcoRI restriction fragments (kb) generated from:</th>
<th>15-kb BamHI-SalI fragment of pXO1.1::Tn917 (tp62)*</th>
<th>24-kb BamHI-SalI fragment of pXO1.1::Tn917 (tp62)*</th>
<th>9.8-kb BamHI-SalI fragment of pXO1.1::Tn917 (tp2A)*</th>
<th>9.8-kb BamHI-SalI fragment of pXO1.1::Tn917 (tp36)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.6</td>
<td>7.3</td>
<td>4.3</td>
<td>4.3</td>
<td></td>
</tr>
<tr>
<td>4.0b</td>
<td>4.3</td>
<td>3.2d</td>
<td>3.1e</td>
<td></td>
</tr>
<tr>
<td>3.3c</td>
<td>3.1c</td>
<td>2.2f</td>
<td>2.2f</td>
<td></td>
</tr>
<tr>
<td>0.8</td>
<td>2.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.72</td>
<td>2.11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.75</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* The BamHI-SalI restriction fragments were isolated from an agarose gel by electroelution and digested with EcoRI.

b Fragment corresponds to the EcoRI-BamHI fragment of the 5.4-kb EcoRI fragment.

c Fragments correspond to the SalI digestion of the Tn917-containing 1.2-kb EcoRI fragment of the plasmid derivative from UM23 tp62.

d Fragment corresponds to the SalI digestion of the Tn917-containing 1.1-kb EcoRI fragment or the 5.2-kb PstI fragment of the plasmid derivative from UM23 tp2A.

e Fragment corresponds to the SalI digestion of the Tn917-containing 1.1-kb EcoRI fragment or the 6.3-kb PstI fragment of the plasmid derivative from UM23 tp36.

f Fragment most likely corresponds to the EcoRI-BamHI junction fragment of a 7.0-kb EcoRI fragment.
Table 8. DNA-DNA hybridization analysis of pXO1.1 (Weybridge A UM23) and pXO1 (Sterne) with the subcloned fragments of each plasmid containing the junctions of the inverted segment

<table>
<thead>
<tr>
<th>Probe(^a)</th>
<th>Hybridization to fragments (kb) of pXO1.1 (Weybridge A UM23) generated by:</th>
<th>Hybridization to fragments (kb) of pXO1 (Sterne) generated by:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><em>BamH_I</em></td>
<td><em>PstI</em></td>
</tr>
<tr>
<td>2.7-kb KpnI insert from pJM12 (part of 5.4-kb EcoRI fragment of pXO1.1 [Weybridge A UM23])</td>
<td>34.8, 14.6</td>
<td>18.7, 9.3</td>
</tr>
<tr>
<td>1.0-kb HindIII insert from pJM14 (part of 2.4-kb EcoRI fragment of pXO1.1 [Weybridge A UM23])</td>
<td>34.8, 14.6</td>
<td>18.7, 9.3</td>
</tr>
<tr>
<td>1.9-kb KpnI insert from pJM16 (part of 4.8-kb EcoRI fragment of pXO1 [Sterne])</td>
<td>34.8, 14.6</td>
<td>18.7, 9.3</td>
</tr>
<tr>
<td>1.7-kb HindIII insert from pJM18 (part of 3.1-kb EcoRI fragment of pXO1 [Sterne])</td>
<td>34.8, 14.6</td>
<td>18.7, 9.3</td>
</tr>
</tbody>
</table>

\(^a\) The probes were isolated from the recombinant plasmids digested with KpnI or HindIII and labelled with digoxigenin-labelled dUTP.
Table 9. Yields of toxin components produced by *B. anthracis* Sterne and Weybridge derivatives

<table>
<thead>
<tr>
<th>Filtrate</th>
<th>PA, µg/mg dry wt.</th>
<th>EF, µg/mg dry wt.</th>
<th>CA-HEPES with bicarbonate and horse serum&lt;sup&gt;b&lt;/sup&gt;</th>
<th>EF, µg/mg dry wt.</th>
<th>CA-HEPES without bicarbonate and horse serum&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Expt. 1</td>
<td>Expt. 2</td>
<td>Expt. 1</td>
<td>Expt. 2</td>
<td>Expt. 1</td>
</tr>
<tr>
<td>Sterne</td>
<td>18</td>
<td>32</td>
<td>7</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>Weybridge UM44-1</td>
<td>48</td>
<td>23</td>
<td>9</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>Weybridge A UM23</td>
<td>34</td>
<td>39</td>
<td>13</td>
<td>10</td>
<td>9</td>
</tr>
</tbody>
</table>

<sup>a</sup> Cultures were grown as described in Table 5. Filtrates were collected from cultures grown for 13 h in broth supplemented with bicarbonate and horse serum or for 14 h in broth without bicarbonate and horse serum.

<sup>b</sup> See Table 2 footnote b.
Table 10. Configuration of glutamic acid in glutamyl polypeptide from
*B. anthracis* 4229 UM12 and insertion mutants tp49, tp50 and tp60

<table>
<thead>
<tr>
<th>Polypeptide from strain</th>
<th>Peptide as glutamic acid&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Total %</th>
<th>L-isomer % of total</th>
<th>D-isomer % of total</th>
</tr>
</thead>
<tbody>
<tr>
<td>4229 UM12</td>
<td>102.3</td>
<td>1.4</td>
<td>98.6</td>
<td></td>
</tr>
<tr>
<td>tp49</td>
<td>115.6</td>
<td>1.3</td>
<td>98.7</td>
<td></td>
</tr>
<tr>
<td>tp50</td>
<td>105.0</td>
<td>1.4</td>
<td>98.6</td>
<td></td>
</tr>
<tr>
<td>tp60</td>
<td>117.6</td>
<td>1.3</td>
<td>98.7</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Strains were grown on minimal IIIB-CO<sub>3</sub> medium.

<sup>b</sup> Results presented are the averages of values from three determinations. The theoretical value for percent glutamic acid in the free acid form of glutamyl polypeptide is 113.9%. 
Figure 1. *BamHI, PstI, EcoRI* restriction maps of the toxin-encoding region of pXO1.1 (Weybridge A UM23). The *BamHI, PstI,* and *EcoRI* restriction maps for a 77-kb region of pXO1.1 from *B. anthracis* Weybridge A UM23 encompassing the toxin structural genes are shown. The map was constructed based on data obtained from single, double, and triple digestions of pXO1.1, pXO1.1::Tn917 derivatives, and deletion derivatives. Results from DNA-DNA hybridization analysis with the cloned toxin structural genes (*pag, lef,* and *cyg*) were also used in the construction of these restriction maps. The locations and directions of transcription of the toxin structural genes and positive activating factor are shown by the arrows. S, SalI.
Figure 3. Cloning of the 2.4- and 5.4-kb EcoRI fragments of pXO1.1 (Weybridge A UM23) and the 3.1- and 4.8-kb EcoRI fragments of pXO1 (Sterne). The fragments were cloned into pBluescriptI KS+ and the cloned inserts are shown. The crosshatched boxes below each insert represent the HindIII and KpnI fragments that were subcloned into pBluescriptI KS+. A, Aval; B, BamHI; C, Clal; E, EcoRI; Ev, EcoRV; H, HindIII; K, KpnI; P, PstI; S, SstI.
Figure 4. Subcloned inserts originating from the 2.4-kb and 5.4-kb EcoRI fragments from pXO1.1 (Weybridge A UM23) and the 3.1-kb and 4.8-kb EcoRI fragments from pXO1 (Sterne). The size of the EcoRI-ClaI fragments in each insert is shown with the line above the insert. With the exception of the EcoRI site, the restriction sites shown above the Y-shaped line represent the restriction sites found in the MCS of pBluescriptIIKS(+). E, EcoRI; S, SstI; C, ClaI; H, HindIII; P, PstI; B, BamHI; A, Aval; Ev, EcoRV; K, KpnI.
Figure 5. Comparison of restriction maps of the toxin-encoding regions of pXO1.1 (Weybridge A UM23) and pXO1 (Sterne). A 77-kb region of pXO1 encompassing the toxin structural genes is shown. The ends of the inversion are shown by the vertical arrows. The crosshatched boxes below the enlarged EcoRI fragments represent the junction fragments of the inverted segments that have been subcloned into pBluescriptIIKS+. The letter "L" or "R" is attached to the cloned fragment designation, i.e. WeyAL, to represent the left and right junction fragments. The subcloned fragments were isolated from the recombinant plasmids and used in DNA-DNA hybridization analysis of the inverted regions of pXO1.1 (Weybridge A UM23) and pXO1 (Sterne). E, EcoRI; C, Clal; K, Kpnl; H, HindIII; A, Aval; and Ev, EcoRV.
WeyAL (pJMH12): 2.7-kb KpnI fragment of the 5.4-kb EcoRI fragment from pXO1.1 (Weybridge A UM23)

WeyAR group

WeyAR (pJMH4): 2.4-kb EcoRI fragment of pXO1.1 (Weybridge A UM23)

pJMH28: 9.3-kb PstI fragment of pXO1.1 (Weybridge A UM23)

Continued next page
Figure 6. Sequencing strategies for the cloned junction fragments of the inverted segments of pXO1.1 (Weybridge A UM23) and pXO1 (Sterne). A partial restriction map of each cloned fragment is shown. The horizontal arrows indicate the direction and extent of sequencing using different synthetic oligonucleotide primers. The vertical arrows represent the direction of subcloning within a particular junction fragment. With the exception of the EcoRI site, the restriction sites shown above the Y-shaped line represent the restriction sites found in the MCS of pBluescriptIIKS(+). E, EcoRI; S, SstI; C, Clal; H, HindIII; P, PstI; B, BamHI; A, Aval; Ev, EcoRV; K, Kpnl.
EcoRI

1 GAATTCCTTC GCAAATAAAA ATACCTCCCT AATCTGAGTG AGGGATGACA
51 TTTTCTACTT TCGGGGCTCT TCCTGCTCTT TTTAACTTCT CCAAACTTAA
101 TGCTAAAGTT TGTAATTACAC TGATGATAA ATCAAGATT TTGAGATTAG
151 AAAGCATCTAT AATGTTGGAAT AAATACACG GTAAGTCTCC AAATAATGAA
201 TACGTTGACAT CTGTAACTCC CTTTTGCGTT GGGTAGCCCA CTTCAGATTG
251 GCAATCTAAT TGAATCGGAAA GTAGAACGG TGCCATATCT TAAATATAT
301 CTAAAAGAGA CCTCCTCCTTC TGATATGCTCTTA TagGACGTCT CTGTGCTCTG
351 TAACCAAGGA TAAAATGTTG GAGGAGTGAA TTCTATATT TTACTCAGTT
401 CGTTGACATT TAAATGTTT ACTTACGGC TATATTTCTA CTCAACTCTG
451 TCACATTGAC TTAGCTTCTTC TGGCTTTCCTC CATAAAGTA TGGTTTTCTC
501 ACAGGTCTTTG GAAGACGGGA CGTTAATCTT ATCAGCACC ATTCATTCA
551 TGTTTAATT TGGGGAACAT TTTTAACTCT CTTTTTCTCA AAATAAGGAA
601 ATATAATAGA CCATCCTCTTT GCGTTCTTCA CTATTTTCTC TTTATTTCTT
651 CTTAGGATATG CACCCCTCTTC TCCAGACGAA AAACACCTCC ATTAATACCA
701 CATACCTAGGT GAACGCAAGCC AGGAAATTCG TACATAAAAAA AAACACCTAT
751 GCTACCTGTT TCTTGTATTC TATAGGACGAC AGGTGGTTTA ACATTCTTG
801 AATACGTTCG GTATATAAT ACTCAAGTGA ATGATGAGTG AGTTGTTTGA
851 GAGTGGAGGT TGAAATGTATT TGGTTTTTCTT GGGATAAAAA CAACTCAGAT
901 TCAATAGGG AATGAAAGAG TCTTATTACG GCATTATCAT GACAATTTC
951 TTTACGGGAC ATACTTGTGG TAAATGCACT TTTTGAATTA AGCTTTGGA
1001 AGCGTGGAGGT GAATCAGGG CCGCTTGAATC ACTATGTAAT AATATGIGG
1051 TCTTTGTTTG CAGTTCTATC GCCTTACTAA CTGTTTTAAA GACGAGTGTT
1101 AGCTACGTAC GTTACATTAT TCGATAGTGA ATGATTTTCT TGTATATAA
1151 ATCCATAATA CTTAAATAAAT ACAACATCTC TGTAACAAAT GCAAATATG
1201 TAAATGCTGT AACACATTTG TAATTTGGGA TTTTCCATTG AGCTTTGGA
1251 TTTAAGAGAT TCTCTACAAC AATTTCTACTT TCTCCATTTG TCCAGGTCTT
1301 TCTCTTTTCT TAAACCCCTAC ATGTAATAT TTTTTTTT GC ATTATTTT
1351 GTACAGTGT TCGATTTGGA TGAATATATA TTGTTGCTTT CAATAAGC
1401 GTAACCTTCT CAGGGCATA TGAAAAGTGA GTGTGACAG TAAATGCTAA
1451 AATAGGCTGT TCTAATTTTG CTTCCCTTAC ATCTTTTCTT TTAATTTTCC

Continued next page
**Figure 7.** Nucleotide sequence of the cloned insert (WeyAI) from pJMH12 (2.7-kb KpnI fragment of the 5.4-kb EcoRI fragment of pXOl.1 from Weybridge A UM23). The sequence starts at the EcoRI restriction site (shown above sequence) and proceeds past the ClaI restriction site (shown above sequence). The start and stop codons of ORF1 (truncated putative transposase gene) and direction of transcription are indicated. The 28-bp inverted repeats of the element are shown with a line above the sequence. The gaps in the line represent deletions or mismatches.
1  CCCTTTGGTA AGGATGTCTT TGGTTGTTTCT CTGTGCTTTG ACTAACCGTA
51  GCAATCTCTGA ATCACCAGCA GTAGTTTGG GGGATCATGA GGAAGAAAAC
101  ACAGAGGAAG CAATACACCC GTATAGCTCA ATATTACAG AAATACTTG
151  TAGTCTACCCT GATTTTGAGG AAGAGGATTG AGGTAACAAA AAACCCGCTC
201  AGGATTTCTGA AGTGAACCCG AATAGTGTTA CATGAAAAAA AACACTCTCCTG
251  AATTCGCTATA CTAACTGAGA TGGACCACGA ATTTGTGACA TGAAAAAAC
301  ACTATATGCTA CCTGTGTTTT GTATCTGATA AGATTTACGT AGTTTAACTT
351  TTCTTGGATA GATTTGCTAT TATAACTCTC AATGTAATCG GGAATTGAGT
401  GTTTGAGAGT AGAAGTTGAA TGTATTTGTT TTTCTGGA AAATACACAT
451  TCAGATTTCA ATGAGGATTG AAGAGATCTT ATTACGCGAT ATACATGACA
501  ATTTCTTTTA CGGAGACATAC TTGTGGAAT TCCACACGCT TGAAAAAAC
551  TTTGGAAAAAGT GTAGGAGGTA TACACGGCCC CTTGATCATC ATGTTGAATA
601  ATTTGAGTCT TTTGTGCGAC TTTATAGCCT TCTCTAGCT TGATTTAACGT
651  GAGTGTTTACG TCTTTGCTGT TACTTATTTG ATATGCAATG AATTTCATTG
701  TATATAACAT CATATATCTT AATAAATACA ACATCTCTGT ACCAAATGGGC
751  AAATATGCTA TGCTTGAAC CCATTTCCTA TTTGGCTTTG TGGCTTTGAA
801  GTTTCTATTT AAGAGATCCT CTCAAACAT TCTACTTCTT CCATTGATCC
851  AGGTCTCTCT CTTCTTTTTA ACCTCAGATT GTAAATTATT TTTTGCGATT
901  ATTTTTTCTA CAGTTTTTCC ATTTGGGGTA TAATTTATTT TTTCTGCAAA
951  TAAAGCAGTA ACTTTTGTCA GGCAATAGTC AAATGTTACT TGCATACAAA
1001 TTTGCAATA TTGCTGCTTT CTTTTGCTTT ATACATTCTT TTTTCTTTTA ClAI
1051 TTTTTCCATC GATAATAAGT AGAAGCGAGG ATACCAATTG ATATACATAT ORF1 GAT-
1101 CTTCTTTAAC AAGGCTCTTT CTTTTTCTTT CTTTTTCTTT Cutl
1151 CTTCTTTAAC CAACTCCTCT CGATTCTTTG GTACCTTTTTT AAAATATCTA HindIII
1201 GTTGCATTTT TAATTTTCTT TCTCTGACTT TGAAGCTTCTC ATTTTCAGTT
1251 ATACCTCTCT CACTTGCCTT TTGTAGCCTG TTTTCTTTCT CTACCAGGGCC
1301 ACTAAAACGA TACGTCTTAC TCCACAGATG CCACCTCCTC CAAGTCTTAA ORF2 GTA-
1351 TCTGTGCTCT ATTTTAAAAA GAGCTTCTT CCCATTTTCT TTTATTTTCT
1401 TATCCCTTTG TTTTCTGATC GATTTTCTCC ATTTTTAATT TCTCTGAAATA
1451 AGATTCTTCT CTACCACGATG AAGAACCACC TCCGATTATT CTATTTTAAA
1501 TTAAATACGG TATAGAGGTT GTTTCTTTCT GTCTTTTTC ATGGGTCAC

Continued next page
<table>
<thead>
<tr>
<th>Start</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1551</td>
<td>TTCATTCAAT GGAGGTGTTT TTCGTTTGAA GACAAGAGTT CATTACCCAG</td>
</tr>
<tr>
<td>1601</td>
<td>AAGAACAAA GTGGAAAGTC ATTGAATGA AGAAAGAAAG TTATTCAAAC</td>
</tr>
<tr>
<td>1651</td>
<td>CGTACAATTA TGGAGAAACT CGGAATTAAA AATGTTTCCA AATTAAGACA</td>
</tr>
<tr>
<td>1701</td>
<td>TGGATGAAAT GGTATCG</td>
</tr>
</tbody>
</table>

Figure 8. Nucleotide sequence of the cloned inserts (WeyAR) from pJMH24 (1.0-HindIII fragment of the 2.4-kb EcoRI fragment of pXO1.1 from Weybridge A UM23), pJMH4 (2.4-kb EcoRI fragment), and pJMH28 (9.3-kb PstI fragment of pXO1.1 from Weybridge A UM23). The sequence starts before the EcoRI restriction site (shown above sequence) and proceeds past the HindIII restriction site (shown above sequence). The CiaI restriction site is also shown. The start and stop codons of ORF1 and ORF2 and the direction of transcriptions are indicated. The 19-bp inverted repeats of the element are shown with a line above the sequence. The gaps in the line represent deletions or mismatches.
# EcoRI

<table>
<thead>
<tr>
<th></th>
<th>GAATTCCGAT ACTAAGTGAA CTGACCCCAGG AATTGGTAC ATGAAAAAAA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>GAT---</td>
</tr>
<tr>
<td>51</td>
<td>CACCTATGCT ACCTGTTTCT TGTATCTAT AGGAGACAGG TAGTTTTACT</td>
</tr>
<tr>
<td>101</td>
<td>TTTCTTGAAAT AGTTCCGTA TTATAATCT CAATGTAATC GTGAATGAGT</td>
</tr>
<tr>
<td>151</td>
<td>TGTTTGAGAG TAGAAGTTGA ATGTATTTGT TTTTCTGGG AATAAAAACG</td>
</tr>
<tr>
<td>201</td>
<td>TTTCTTGAAAT AGTTCCGTA TTATAATCT CAATGTAATC GTGAATGAGT</td>
</tr>
<tr>
<td>251</td>
<td>AATTTCTTTT ACCGGAACATA GTGTTGTAAA TGGCATTTTT TTTAGATAAC</td>
</tr>
<tr>
<td>301</td>
<td>GATTTGGAAG GTTAGGAGGT ATACACGGCC CTTGATCAC TAGTAGATAT</td>
</tr>
<tr>
<td>351</td>
<td>AATTTGAGTC TTTTGTGCA GTTTATCGC TTCTCAACT GTTCTAAAGA</td>
</tr>
<tr>
<td>401</td>
<td>CGAGTGTACGTCTTGCTGT TTTACTTTAT CATATGCAAT GATTTCTTG</td>
</tr>
<tr>
<td>451</td>
<td>TTATAATAAT CCATAACTCT TAATAATAC AACATCTCTG TACAAAAAGG</td>
</tr>
<tr>
<td>501</td>
<td>CAAATATGTA ATGTCTGTA ACCATTTTTT ATTGGCTGG TAGCTGAAA</td>
</tr>
<tr>
<td>551</td>
<td>AGTTTCTATT TAAGAGATT TCTACAACAA TTTCTATTT CTTTATTGTAC</td>
</tr>
<tr>
<td>601</td>
<td>CAGTTTCTTC TCTTCTTTTT AACCTACAT TGTAATTTT TCTTTTCGAT</td>
</tr>
<tr>
<td>651</td>
<td>TATTTTTGTT CAGTTTTTTT GATTTGGGGA TTAATTATAT TTTGTTTTCA</td>
</tr>
<tr>
<td>701</td>
<td>ATAAAGCAGT AACTTTTCCA TGGCCATATC GAAATGATT GTCTACAAAC</td>
</tr>
<tr>
<td>751</td>
<td>AATGTCAAAAC TAGCTCTGTA TAAATTTGCT CTCTTAACAT CTTTTCTTTT</td>
</tr>
<tr>
<td>801</td>
<td>ATTCCCCAT CGATAATAAG TAGAAGCAGG TATAACCAAT AAT---ACATA</td>
</tr>
<tr>
<td>851</td>
<td>---ORF1---GTA</td>
</tr>
<tr>
<td>901</td>
<td>TCTCTATAAT GGAGTACTCA TCTTCATCA ACTCCACTAC TTTATTTATC</td>
</tr>
<tr>
<td>951</td>
<td>ACTTCTTTAA CCAACTCCTC TCGATTTCAG TTATGCTTTC TTCACTAGTC</td>
</tr>
<tr>
<td>1001</td>
<td>TTTTGTCAGG TAGTTTCTTT TCTTACAGGG CAGTTAAAC GATACGTTTC</td>
</tr>
<tr>
<td>1051</td>
<td>ACCTTCAGA TGCCACTTCA TCAAAGTTTT ATACTGTTCT TATAATTTAA</td>
</tr>
<tr>
<td>1101</td>
<td>TTTCTTAATT TCCTACATAA TCTTTGTTTG GTATCTTTG TTTTTTTTCAG</td>
</tr>
<tr>
<td>1151</td>
<td>TGCATTGTT TTCCATTAA TTTCTCTGA ATAGATTCTCTCGTTCCCA</td>
</tr>
<tr>
<td>1201</td>
<td>TAAAGAAGAA ACCTCCGTAT ATTCGTATTT ATTTAAATA CGGATAAGA</td>
</tr>
<tr>
<td>1251</td>
<td>ATTTATGGA GTGTTTTTT TCTAGCTCAC TATTCGATT CACTTACAGT</td>
</tr>
</tbody>
</table>

Continued next page
Figure 9. Nucleotide sequence of the cloned insert (StemeL) from pJMH16 (1.9-kb KpnI fragment of the 4.8-kb EcoRI fragment of pXO1 from Sterne). The sequence starts at the EcoRI restriction site (shown above sequence) and proceeds past the CiaI restriction site (shown above sequence). The start and stop codons of ORF1 and the direction of transcription are indicated. The putative 28-bp inverted repeats of the element are shown with a line above the sequence. The gaps in the line represent deletions or mismatches. The complete sequence of the right inverted repeat (shown at the beginning of this sequence) is not shown because no sequence was obtained before the EcoRI restriction site.
EcoRI

1  GAATTCCTTC GCAATATAAA ATACTTCTTT AATCTGAGTG ACGGATGACA

51  TTTTCTACTT TTGGGCTCTTC TCCTGCTCGTT TTTAACTTCC TCAAATCTAA

101  TGTCAAAGATTT GTAATTCCAC TGTAGTATAA ACTAATGATT TCACGATTAG

151  AAGCATCTAT AATCGTTGAT AAATACAACG TAAGCTCTCC AAATAATAGA

201  TACGTGACAT CTGTAACCTCC CTTTTCGGTT GGGATTGCCA CTTCGAAATTG

251  GCATTCTAAAT AGCGCGAGCA CTAGAAGCAG TTCCATATCT TAAATTTATAT

301  CTAAAAACAGA CCCCCTCTTTC TGATATCGTTCTT TTAGACGGTT CTGTGTCTG

351  TAACCAACGA TAAAATGTGG AACGTGCTAA TTCTAATTAT TTTCTCAGTT

401  CTTGTATGTT TAAATTTTGGT TATTACGCCGTT TATTTCTTCA TCAAAACTG

451  TCCAAATTCC TTAAGCTCTTT TGCGTTTTCC CATAAAAAGTA TTGTGTTTCC

501  ACGTTTTGT TAAGAGGCGTA CGTTTAACTC ATTCAGACCC ATTTCAATTCA

551  TGGGTAAATT TGCGGACAAAT TTTAATTTCT GGTGAAAACTAA AATTAAAGGA

601  ATTATAATGA CCATCTCTGT TCAATTTCTT CGCATTTTAC TTTATTTCTT

651  CTAGATAATG CACCCCTTTC TCCTAAACAGAA AAACACCTCC ATTTAAATCC

701  CATACTAAGT GAACGTACCAC AGCAATTTGG TACATAAAAA AAACACCTAT

751  GCATACCTTT TCTTGATTTCC TATAGGAGAC AGGTAGTTTA ACTTTTCTTG

801  AATACGGTTCG ATATTATAACTCTCAAATGAATGTGGAAG ATGTGTGTGA

851  GAAGTAAAGT GAAATTGTATT TTTTTTTCTTG GGGATAAAAA CAATTCGATA

901  TTCAATGGAGG AATGAAAAAG TCTATTACGG GCATTATCAT GAAATTCTCC

951  TTTACGGGAC ATACTTGTTGG TAATTGGAATTTA TTTTTAGATA AGTTTTGGAA

1001  AGCGTGGAGG ATATACCCAGG CCCCTTGATCA CTATATGAGTTA ATAAATTTGAG

1051  TCTTTTGGTG CAGTGGTATCC GTGTCTTCAA CTGTGTCTAA GACGAGTGGTT

1101  ACCTCTGTGC TCTATTCTAT TCTCATATGAA ATGATTCTTT TTTATATAAA

1151  ATCCATAATA CTTAATTTAA CATCCATCTC TGTACCAAAAT GACCAAATATG

1201  TAATGCTCTGT AAACCTTATT TGTATGCTGT TGTAGCTGT TAAGTTTTGA

1251  TTTAAGGAGT TCTCTACACG AAATTCTACTT TCTCCATTGA TCCAGTTCTT

1301  TCTCTTTTCT TTAACCCCTAC ATTTGAAATTT TTCTTTTGC ATTAATTTTTT

1351  GTACAGTTTT TCGATTGGGA TGATAATTAT TTTTGGTTTA CAAATAAGCA

1401  GTAACTTTTC GATGGCCATA TCGAAAGTGA TTTGTCATAC AAATTTGTCAA

1451  ATAGGCTCTG TCTAATTTTTG CTTCCCTTAC ATTCCTTTCT TTATTTTCTCC

Clai

1501  ATCTGATAATA ATGGAGCGTA GGTATACCCC TTAATATAGA TATCTTTTTA

Continued next page
Figure 10. Nucleotide sequence of the cloned inserts (SterneR) from pJMH2O (1.7-kb HindIII fragment of the 3.1-kb EcoRI fragment of pXO1 from Sterne) and pJMH5 (3.1-kb EcoRI fragment). The sequence starts at the EcoRI restriction site (shown above sequence) and proceeds past the HindIII restriction site (shown above sequence). The ClaI restriction site is also shown. The start and stop codons of ORF1 (truncated putative transposase gene) and direction of transcription are indicated. The 19-bp inverted repeats of the element are shown with a line above the sequence. The gaps in the line represent deletions or mismatches.
Figure 11. Bestfit of sequences of WeyAR and WeyAL. The Clal and HindIII restriction sites are shown with the HindIII site underlined. The start and stop codons of ORF1 for WeyAR and WeyAL are shown above or below the sequences. The 19-bp and 28-bp inverted repeats of WeyAR and WeyAL, respectively, are shown with the lines above or below the sequences. Deletions or gaps within the sequences are shown by a period. A direct repeat in WeyAR is shown by double lines above the sequence and may have been involved in the formation of the deletion of this region in WeyAL. The sizes of the inverted repeats/IS elements are approx. 1336 bp in size.
Figure 12. Best fit of sequences of Stemel- and SterneR. The Clal and HindIII restriction sites are shown with the HindIII site underlined. The start and stop codons of ORF1 for Stemel- and SterneR are shown above or below the sequences. The 28-bp and 19-bp inverted repeats of Stemel- and SterneR, respectively, are shown with the lines above or below the sequences. Only 3 nt of the left 19-bp inverted repeat of SterneR are shown (nt695 to nt697). Only 12 nt of the right 28-bp inverted repeat of Stemel- are shown (nt2 to nt13) because a fragment of pXO1 (Sterne) containing the remaining sequence of the inverted repeat has not been cloned or sequenced. Deletions or gaps within the sequences are shown by a period. A direct repeat in SterneR is shown by double lines below the sequence and may have been involved in the formation of the deletion of this region in Stemel-. The sizes of the inverted repeats/IS elements are approx. 1336 bp in size.
Figure 13. Partial restriction maps of the junction fragments of the toxin-encoding regions of pXO1.1 (Weybridge A UM23) and pXO1 (Sterne). Based on sequence analysis, possible sites of the junctions of the inverted segment are represented by the open and crosshatched boxes. The thin arrows show the locations of the ca. 1.3-kb inverted repeats/IS elements. E, EcoRI; C, ClaI; K, KpnI; H, HindIII; A, Avai; and Ev, EcoRV.
Figure 14. Locations of major ORFs in the cloned junction fragments of the inverted segments of pXO1.1 (Weybridge A UM23) and pXO1 (Sterne). The directions of transcription and the sizes of the ORFs are shown. With the exception of the EcoRI site, the restriction sites shown above the Y-shaped line represent the restriction sites found in the MCS of pBluescriptIKS(+) . E, EcoRI; S, SstI; C, CiaI; H, HindIII; P, PstI; B, BamHI; A, Aval; Ev, EcoRV; K, KpnI.
Figure 15. Restriction map of pXO2. The locations of Tn917 insertions are indicated by the arrows. Insertion mutants that exhibit the parental phenotypes are not labeled with phenotypic designations. Deletions are indicated by dotted lines.

Cap-, inability to produce capsule; Cap++, CO₂-independent for capsule production; Cap⁺⁺⁺, overproduction of capsular material in CO₂.
REFERENCES


APPENDIX

List of Publications

Papers


Ph. D. Dissertations


Abstracts


List of Personnel

Principal Investigator: C. B. Thorne, Professor of Microbiology

The following graduate students in pursuit of the Ph. D. degree worked on the project:

Jan M. Hornung (Continued to work on the project as a postdoctoral appointee after she was awarded the Ph. D. degree in May 1994).

Ana Guaracao-Ayala

The following person was employed as a technician for part of the contract period:

James Silva
The following undergraduate students were employed on an hourly basis for various periods of time as laboratory workers:

Jeremy Jorgenson  
Bradford Burling  
Steven Ellis  
Sheryl Egan  
Maureen Connor

List of Those Who Received Graduate Degrees While Working on the Contract:

Ana Guaracao-Ayala (September 1993)

Jan M. Homung (May 1994)